KR20200123027A - Anti-angiogenic fusion polypeptides, fusion protein cages with multivalent dual anti-angiogenic peptides, and their theranostics applications - Google Patents

Abstract

The present invention provides an anti-angiogenic fusion polypeptide, a fusion protein nanocage having the anti-angiogenic peptide, and application of the same to diagnostics and treatment (theranostics). The fusion protein nanocage of the present invention presents a new path for advanced drug delivery systems to treat angiogenesis-related diseases.

Description

Anti-angiogenic fusion polypeptides, fusion protein cages with multivalent dual anti-angiogenic peptides, and their theranostics. {Anti-angiogenic fusion polypeptides, fusion protein cages with multivalent dual anti-angiogenic peptides, and their theranostics. applications}

The present invention relates to a fusion polypeptide for inhibiting neovascularization, a fusion protein nanocage having the peptide for inhibiting neovascularization, and a diagnosis and treatment (theranostics) thereof.

Proteins in organisms are self-assembled into well-ordered structures to exert biological functions, and self-assembled structures and their biomedical applications are being actively studied. Well-ordered protein structures perform important functions within cells and organisms, such as genome packaging, structural support, and biological elements of storage and transport. Self-assembly is manufactured by assembling protein subunits in a bottom-up manner, and has various structures such as nanofibers, ring-like structures, and cage structures. Proteins that form these structures have been studied and developed in biomedical applications in the form of their original structures or materials. One of the well-ordered proteins is a linear protein such as collagen, amyloid, and tubulin, which forms nanofibrous structures. Linear proteins such as collagen are prepared as films, sheets or hydrogels for drug delivery systems. The collagen film or sheet coats or carries the drug by chemical conjugation or physical entrapment to control drug release. Fibrous proteins, such as tubulin, are fused with biotin to immobilize the protein structure on the target surface, or act with antibodies to carry the target protein. Other well-ordered proteins are circular proteins such as β-clamp or trp RNA-binding attenuation protein (TRAP). The functions of these circular proteins are associated with unwinding into single stranded DNA, unwinding of supercoiled DNA, and DNA transport or DNA manipulation by binding to DNA or RNA. Another protein structure is the closed shell structure of cage proteins such as ferritin or viral capsid. The cage structure is used as a small-reactor or drug carrier in the empty interior, and is fused with a functional peptide such as a receptor to act on the outer shell. These protein structures are developed for advanced drug delivery systems by fusing with other functional peptides or chemicals such as fluorescent dyes or drugs.

Protein-based structures have the advantages of biocompatibility and biodegradability in biomedical applications. One of these protein structures is ferritin, which refers to a self-assembled nanocage structure of four helix bundles and relatively short helixes. Ferritin is a family of iron storage proteins in organisms and has reversible pH reactivity. Ferritin decomposes under strong acid conditions (pH 2) and reassembles under neutral pH conditions. Ferritin's reversible pH reactivity is used in several applications and in the construction of new chimera proteins. For example, if ferritin was chemically conjugated to two kinds of fluorescent dyes, respectively, the two kinds of different chemical dye-conjugated ferritins were mixed and decomposed with decreasing pH. The pH was then adjusted to the natural pH to restore the original cage structure. The ferritin hybrid unit labeled with two different dyes was used as a probe with fluorescence resonance energy transfer (FRET) to discriminate the tracking signal from ferritin and degraded molecules. Another major feature of ferritin is its ability to store iron. In organisms, ferritin is essentially an iron storage protein. Meanwhile, many previous studies have confirmed that ferritin stores metal ions such as gold, lead and copper. Certain amino acids in the pores of the ferritin structure have binding specificities, and the amino acid sequence varies depending on the ion. For example, gold ions (Au ³⁺ ) coordinated with Cys48, His49, Met96, His114 and Cys126, and lead ions (Pd ²⁺ ) were accumulated in the center of Glu45, Cys48, Arg52, Glu53 and His173. Accumulated metal ions are reduced to metal nanoparticles by reduction of the cavity inside the cage structure, and the ferritin-metal nanoparticle complex is used as a catalyst, magnetic resonance imaging (MRI), and imaging probe for PET (positron emission tomography). Became. In order to explain the additional function of ferritin, ferritin fragments were replaced with other functional peptides or proteins, or introduced on the surface exposed to the outside of ferritin. For example, a pH-responsive peptide or a cell-targeting peptide has been genetically engineered with ferritin. Despite ferritin's pH-reactivity, its pH range is too extreme (pH 2), so the GALA peptide as a pH-responsive peptide replaced the C-terminal short helix. GALA peptide has an arbitrary coil shape under neutral pH conditions, and morphological changes occur in a spiral shape under acidic conditions (pH 6) to decompose the cage structure. Another functional peptide was introduced at the two exposed sites of ferritin, intermediate the N-terminus and the fourth helical bundle and the short helix. In the previous study, interleukin-4 receptor (IL-4R)-targeting peptide coil and peptide (AP-1) was genetically fused between the fourth helical bundle and short helix of ferritin, and the IL-4R-expressing cell line of fused ferritin. , Binding and internalization to A549 have been reported. Ferritin was also genetically fused with RGD-4C, which binds α _V β ₃ , which positively feeds back tumor vasculature as another cell-specific targeting peptide. Meanwhile, the cell-specific targeting ability of RGD-4C fused with ferritin to melanoma cells was also confirmed.

Elastin is a major component of proteins in the extracellular matrix (ECM), and is composed of an elastomeric domain and a crosslinking domain. The elastomeric domain consists of hydrophobic amino acids and repetitive peptides such as VPGG, VPGVG, and APGVGV. Elastin-based polypeptides (EBPs) are thermally reactive biopolymers derived from elastomer domains. Elastin is a major protein component in the extracellular matrix (ECM). EBPs were modified to have thermal sensitivity based on the elastomer domain, and Val-Pro-(Gly or Ala)-X, a repeating unit of pentapeptide, a peptide composed of five amino acids. _aa -Gly[VP(G or A)XG]. EBPs are heat-sensitive polypeptides, and their transition temperature is easily controlled to form drug delivery nanostructures.

The X _aa is a guest residue and may be any amino acid except proline. Depending on the sequence of the repeating unit, it can be classified into two types of EBPs. One is an elastin-based polypeptide with elasticity (EBPE) whose sequence is Val-Pro-Gly-X _aa -Gly. ), and the other is an elastin-based polypeptide with plasticity (EBPP) having a sequence of Val-Pro-Ala-X _aa- Gly.

EBPs are designed to have stimulus-responsiveness, biocompatibility, biodegradability, and non-immunity based on elastomeric domains. EBPs are thermally reactive biopolymers and are composed of Val-Pro-(Gly or Ala)-X _aa -Gly, which are many'pentapeptide repeating units', where X _aa is the 4th amino acid in the repetitive unit. It can be any amino acid except Pro. EBPs have a lower critical solution temperature (LCST) behavior and show a reversible phase transition with temperature. Their LCST behavior has the advantage of enabling inverse transition cycling (ITC) based on protein purification methodology using thermally induced phase transitions of EBPs. The easy purification and stimulation-induced phase transition of EBPs allows for the genetic fusion of other functional proteins and peptides. For example, EBPs are genetically fused with intein, a self-cleaving protein, without affinity chromatography or proteolytic tag removal, and chlorophenicol acetyltransferase (Chloramphenicol). acetyl transferase (CAT) or thioredoxin (Thioredoxin, Trx) was used as a protein purification tag to increase the production of target proteins. Soluble EBPs are'inert protein-based biomaterials' such as polyethylene glycol (PEG) and'drugs' along with drugs or other functional proteins for advanced drug delivery systems, regenerative medicine, and tissue engineering. It functions as'drug delivery carriers'.

Recently, it has been known that a significant number of cancer-related-diseases are due to abnormal angiogenesis in the tumor. Physiological angiogenesis in organisms is only activated under specific conditions by tight control. One of the strategies for controlling angiogenesis is to convert vascular endothelial growth factor (VEGF) into two types of VEGF receptors (VEGFR), VEGFR1 (fms-like tyrosine kinase-1 or Flt1) and VEGFR2 (kinase). insert domain-containing receptor or Flk-1/KDR) and initiate growth signals in vascular endothelial cells. Abnormal formation of blood vessels due to disruption of regulation causes diseases such as cancer as well as non-neoplastic diseases. Therefore, in order to inhibit angiogenesis in various diseases such as tumor growth, cancer cell metastasis, retinal angiogenesis, choroidal neovascularization, diabetic retinopathy, and asthma, various strategies for anti-angiogenesis have been applied. Examples include initiating anti-angiogenic signaling using angiogenesis inhibitors such as pigment epithelial-derived factor (PEDF) of caffeic acid (CA), and VEGF initiating its receptors ( VEGFRs), thereby blocking angiogenesis signals. Although the specific functions of each VEGFRs have not been fully elucidated, the fact that VEGFR1 and VEGFR2 induce neovascularization through different effects has been confirmed by gene deletion studies. In mice without VEGF and VEGFR1 genes, endothelial cells overgrowth and blood vessels were not formed. Rat endothelial cells and hematopoietic cells without VEGF and VEGFR2 genes did not develop normally. In order to suppress neovascularization without damaging endothelial cells and hematopoietic cells, a strategy was developed to prevent the binding of VEGF and VEGFR1 using a biomacromolecule or peptide having a high affinity for VEGFR1. Anti-Flt1 peptide identified through the search for a positional scanning-synthetic peptide combinatorial library (PS-SPCL), which is one of high throughput screening (HTS) systems, is Gly-Asn-Gln-Trp-Phe-Ile (GNQWFI It is a hexapeptide having an amino acid sequence of ). Anti-Flt1 peptide is a VEGFR1-specific antagonist that specifically binds to VEGFR1, whereby VEGFR1 interacts with all VEGFR1 ligands, including VEGF as well as placental growth factor (PIGF) and VEGF/PIGF heterodimer. Interfere with things. In order to increase the half-life of the Anti-Flt1 peptide in vivo , the Anti-Flt1 peptide-hyaluronate (HA) conjugate is genistein, dexamethasone, or tyrosine. In the formation of self-assembled micelle structures incorporating -specific protein kinases inhibitors. Although the conjugation of the HA polymer with the Anti-Flt1 peptide increases the half-life of the Anti-Flt1 peptide in the body, the conjugation efficiency and micelle structure are the polydispersed HA polymer molecular weight, random distribution, and HA and Anti-Flt1 peptide. There is a problem of being heterogeneous due to the inconsistency of the conjugation efficiency of the Flt1 peptide.

Another strategy for inhibiting angiogenesis is to activate anti-angiogenic signals. Pigment epithelial-derived factor (PEDF) not only activates anti-angiogenesis signals, but also plays a role in maintaining balance with angiogenesis as an angiogenesis inhibitor, and has neurotrophic and antitumorigenic properties. Two types of PEDF peptides, PEDF 44-mer peptide (residue 58-101) and PEDF 34-mer peptide (residue 24-57), and their functions were investigated along with the mechanism. PEDF 44-mer peptide prevents vascular leakage and has a neurotrophic function. In tumor cells, the PEDF 44-mer peptide induces neuroendocrine differentiation and neuronal outgrowth. PEDF 34-mer peptide has the function of inhibiting neovascularization and tumor cells through various pathways. PEDF 34-mer peptide activates c-jun-NH2 kinases (JNK) and inactivates nuclear factor of activated T cells (NFAT). Activated JNK interferes with the expression of endogenous caspase inhibitors and c-FLIP (cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein) for apoptosis and inhibits the expression of NFAT. Restore the state of inactivation. Inactivated NFAT interferes with basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF)-induced transcription to inhibit neovascularization. The PEDF 34-mer peptide has a binding affinity to the catalytic β-subunit of the F1-ATP synthase, which is to inhibit ATP synthase activity. Lack of ATP on the cell surface leads to restriction of tumor growth and invasion. PEDF 34-mer peptide has a binding affinity to the laminin receptor of the endothelial cell membrane. Laminin is a major component of the basal lamina, one of the basic membranes located under the endothelial cells. PEDF 34-mer peptide, including laminin receptor, causes apoptosis of endothelial cells and inhibits tube formation.

The present inventors have completed the present invention by continuing the study of introducing stimulus-responsive elastin-based polypeptides (EBPs) into a helix-based cage-type nanostructure.

Korean Patent Registration No. 10-1296329

Biomaterials 31 (2010) 5191-5198

It is an object of the present invention to provide a novel fusion polypeptide for inhibiting neovascularization.

Another object of the present invention is to provide a composition for the treatment of diseases caused by neovascularization, including the fusion polypeptide for inhibiting new angiogenesis.

Another object of the present invention is to provide a fusion protein nanocage having a peptide for inhibiting neovascularization.

Another object of the present invention is to provide a theranostic nanoprobe for diseases caused by the generation of new blood vessels.

The present invention,

i) anti-angiogenic peptides; A helix-based polypeptide represented by SEQ ID NO: 1 linked to the peptide; A hydrophilic elastin-based polypeptide linked to the peptide (hydrophilic EBP); Consisting of a helix-based polypeptide represented by SEQ ID NO: 2 linked to the hydrophilic EBP, or

ii) a helix-based polypeptide represented by SEQ ID NO: 1; Hydrophilic EBP linked to the helix-based peptide; An anti-angiogenic peptide linked to the first hydrophilic EBP; A second hydrophilic EBP linked to the anti-angiogenic peptide; And a helix-based polypeptide represented by SEQ ID NO: 2 linked to the hydrophilic EBP, or

iii) anti-angiogenic peptides; A helix-based polypeptide represented by SEQ ID NO: 1 linked to the peptide; Hydrophilic EBP linked to the protein; Anti-angiogenic peptide linked to the hydrophilic EBP; Hydrophilic EBP linked to the anti-angiogenic peptide; And it is composed of a helix-based polypeptide represented by SEQ ID NO: 2 linked to the hydrophilic EBP, it provides a fusion polypeptide for inhibiting new angiogenesis.

The anti-angiogenic peptide may be an anti-Flt1 peptide [SEQ ID NO: 3] or PEDF (pigment epithelial-derived factor) 34-mer [SEQ ID NO: 4], but is not limited thereto.

The PEDF 34-mer is an anti-angiogenic functional 34 amino acid region in PEDF, and is already known in the art.

The anti-Flt1 peptide specifically binds to Flt1, a Vascular Endothelial Growth Factor (VEGF) receptor, and inhibits the creation of new blood vessels. PEDF (pigment epithelial-derived factor) is a peptide that inhibits angiogenesis.

The hydrophilic EBP may be one represented by one of SEQ ID NOs: 5 to 14, but is not necessarily limited thereto, and all hydrophilic EBPs usable in the art may be included.

The i) may be composed of [anti-Flt1 peptide of SEQ ID NO: 3]-[helix-based polypeptide represented by SEQ ID NO: 1]-[hydrophilic EBP]-[helix-based polypeptide represented by SEQ ID NO:2] .

The ii) is [Helix-based polypeptide represented by SEQ ID NO: 1]-[Hydrophilic EBP]-[PEDF 34-mer of SEQ ID NO:4]-[Hydrophilic EBP]-[Helix-based polypeptide represented by SEQ ID NO:2] It can be composed of.

The iii) is [anti-Flt1 peptide of SEQ ID NO: 3]-[Helix-based polypeptide represented by SEQ ID NO: 1]-[hydrophilic EBP]-[PEDF34-mer of SEQ ID NO:4]-[hydrophilic EBP]-[sequence Helix-based polypeptide represented by number 2].

I) may be represented by SEQ ID NO: 16, ii) may be represented by SEQ ID NO: 17, and iii) may be represented by SEQ ID NO: 18.

In another aspect, the present invention provides a composition for the treatment of diseases caused by neovascularization, including the above-mentioned fusion polypeptide for inhibiting neovascularization.

Diseases caused by neovascularization include diabetic retinopathy, retinopathy of premature infants, macular degeneration, choroidal neovascularization, neovascular glaucoma, ocular disease due to corneal angiogenesis, rejection during corneal transplantation, Corneal edema, corneal opacity, cancer (cancer), hemangioma, hemangiofibroma, rheumatoid arthritis (rheumatoid arthritis), and may be any one or more selected from psoriasis, but is not limited thereto.

In another aspect, the present invention is prepared by self-assembling a helix-based polypeptide represented by SEQ ID NO: 1 and a helix-based polypeptide represented by SEQ ID NO: 2 in the aforementioned fusion polypeptide for inhibiting neovascularization. , It provides a fusion protein nanocage having a peptide for inhibiting neovascularization.

The nanocage may have a multivalent fusion polypeptide for inhibiting new angiogenesis.

In one embodiment of the present invention, it has an anti-Flt peptide and PEDF 34-mer at the same time.

In another aspect, the present invention,

Fluorescent dyes; And

A fusion protein nanocage having a peptide for inhibiting neovascularization as mentioned above; consisting of, wherein the fluorescent dye is contained in the nanocage, a theranostic nanoprobe for diseases caused by neovascularization ( theranostic nanoprobe).

In another aspect, the present invention,

Metal nanoparticles bound with Raman dye; And

A fusion protein nanocage having the aforementioned peptide for inhibiting neovascularization;

It comprises, and the Raman dye is bound metal nanoparticles are contained in the nanocage, providing a theranostic nanoprobe for diseases caused by the generation of new blood vessels.

Diseases caused by neovascularization include diabetic retinopathy, retinopathy of premature infants, macular degeneration, choroidal neovascularization, neovascular glaucoma, ocular disease due to corneal angiogenesis, rejection during corneal transplantation, Corneal edema, corneal opacity, cancer (cancer), hemangioma, hemangiofibroma, rheumatoid arthritis (rheumatoid arthritis), and may be any one or more selected from psoriasis, but is not limited thereto.

The term "anti-angiogenic peptide" as used in the present invention refers to a peptide that inhibits the formation of new blood vessels. As a specific example, the anti-Flt1 peptide specifically binds to Flt1, a Vascular Endothelial Growth Factor (VEGF) receptor, to inhibit new blood vessel generation. PEDF (pigment epithelial-derived factor) 34-mer is a peptide that inhibits angiogenesis.

The fusion polypeptide of the present invention acts to inhibit the generation of new blood vessels.

The term "amino acid" used in the present invention means natural 　 amino acid 　 or artificial 　 amino acid, and preferably natural 　 amino acid. For example, the amino acid refers to glycine, alanine, serine, valine, leucine, isoleucine, methionine, glutamine, asparagine, cysteine, histidine, phenylalanine, arginine, tyrosine, or tryptophan.

The properties of these amino acids are well known in the art. Specifically, it exhibits hydrophilicity (negative charge or positive charge) or hydrophobicity, and also exhibits aliphatic or aromatic properties.

Abbreviations such as Gly (G) and Ala (A) used in the present specification are amino acid abbreviations. Gly stands for glycine and Ala stands for alanine. Glycine is also expressed as G, and alanine is expressed as A. The abbreviation is a widely used expression in this technical field.

In the present invention, the term "hydrophilic amino acid" refers to an amino acid exhibiting hydrophilic properties, such as lysine and arginine.

The term "polypeptide" as used herein refers to any polymeric chain of amino acids. The terms "peptide" and "protein" can be used interchangeably with the term "polypeptide", which also refers to a polymer chain of amino acids. The term "polypeptide" includes natural or synthetic proteins, protein fragments, and "polypeptide" analogs of protein sequences. Polypeptides can be monomeric or polymeric.

"Elastin-based polypeptides (EBPs)" of the present invention are also referred to as "elastin-like polypeptieds (ELPs)". It is a term widely used in the technical field of the present invention.

In the present specification, the X _aa (or X) is referred to as "guest residue". Various types of EBP according to the present invention can be prepared by introducing variously X _aa .

The EBP undergoes a reversible phase transition at a lower critical solution temperature (LCST) also referred to as a transition temperature (T _t ). These have high water solubility below T _t , but become insoluble when the temperature exceeds T _t .

In the present invention, the physicochemical properties of EBP are mainly controlled by the combination of the pentapeptide repeating unit Val-Pro-(Gly or Ala)-X _aa- Gly. Specifically, the third amino acid of the repeating unit determines the relative mechanical properties. For example, in the present invention, the third amino acid, Gly, determines elasticity, or Ala determines plasticity. The elasticity or plasticity is a property that appears after transition.

On the other hand, the hydrophobicity of the guest residue X _aa , which is the fourth amino acid, and the polymerization of the pentapeptide repeating unit, both affect T _t .

The EBP according to the present invention may be a polypeptide in which a pentapeptide is repeated, and the repeated polypeptide may form a polypeptide block (EBP block). Specifically, a hydrophilic EBP block or a hydrophobic EBP block may be formed. The hydrophilic or hydrophobic property of the EBP block of the present invention is closely related to the transition temperature of EBP.

The transition temperature of EBP also depends on the amino acid sequence and its molecular weight. Urry et al. performed many studies on the correlation between EBP sequence and T _t (Urry DW, Luan C.-H., Parker TM, Gowda DC, Parasad KU, Reid MC, and Safavy A. 1991. Temperature of polypeptide inverse temperature transition depends on mean residue hydrophobicity.J. Am. Chem. Soc. 113: 4346-4348.). Urry et al. In the pentapeptide of Val-Pro-Gly-Val-Gly, when the 4th amino acid "guest residue" is substituted with a residue more hydrophilic than Val, T _t increases compared to the original sequence, and conversely, more hydrophobic than Val It was found that substituting a guest residue with a residue lowered the T _t than the original sequence. That is, it was found that hydrophilic EBP has a high T _t and hydrophobic EBP has a relatively low T _t . Through these findings, it was possible to prepare EBP having a specific T _t by determining which amino acid to use as a guest residue of the EBP sequence and changing the composition ratio of the guest residue (Protein-Protein Interactions: A Molecular Cloning Manual). , 2002, Cold Spring Harbor Laboratory Press, Chapter 18. pp. 329-343).

As described above, the high _t T represents the hydrophilic represents a hydrophobic if T _t is low. EBP blocks according to the present invention can also raise or lower T _t by changing the amino acid sequence and molecular weight including guest residues. Thus, it is possible to prepare a hydrophilic EBP block or a hydrophobic EBP block.

For reference, EBP having a T _t lower than body temperature may be used as a hydrophobic block, and EBP having a T _t higher than body temperature may be used as a hydrophilic block. Due to these properties of EBP, the hydrophilic and hydrophobic properties of EBP can be relatively defined when applied bioengineering.

For example, the EBP sequence of the present invention is a plastic polypeptide block in which the plastic pentapeptide of Val-Pro-Ala-X _aa- Gly is repeated and the elastic pentapeptide of Val-Pro-Gly-X _aa- Gly is repeated elastic polypeptide. When comparing the blocks, the third amino acid, Gly, shows higher hydrophilicity than Ala. Therefore, the plasticity polypeptide block (Elastin-based polypeptide with plasticity: EBPP) appears to have a lower T _t than the elastic polypeptide block (Elastin-based polypeptide with elasticity: EBPE).

As described above, EBPs according to the present invention are capable of exhibiting hydrophilic or hydrophobic properties by controlling T _t .

The "helix-based polypeptide" of the present invention means a helical polypeptide, specifically derived from ferritin.

Ferritin is a protein in the cell that stores and releases iron. Ferritin self-assembles to create a protein cage. Cage protein is a protein capable of forming a macromolecule of tens to hundreds of times the molecular weight of a monolith by the precise self-assembly property of low molecular weight monoliths. Ferritin is generally in the form of a hollow spherical cage in vivo, and consists of a spiral bundle (ferritin A, B, C, D) and a short fifth helix (ferritin E).

The helix-based polypeptide of the present invention is also described as "HPC (helix-based protein cage)", and SEQ ID NO: 1 (indicated as'HPC4' in the examples), which is a spiral bundle (ferritin A, B, C, D), and , Is represented by the short fifth helix (ferritin E), SEQ ID NO: 2 (indicated as'HPC5' in the examples).

In the present invention, the term "theranostic nanoprobe" refers to a nano-sized probe capable of simultaneously performing therapy and diagnosis.

The term "nano" includes a size range that is understood by those skilled in the art. Specifically, the size range may be 0.1 to 1000 nm, more specifically 10 to 1000 nm, more preferably 20 to 500 nm, and even more preferably 40 to 250 nm.

In the present invention, the term "Raman dye" refers to an organic compound used in a measurement method based on surface-enhanced Raman scattering (SERS). Using the metal nanoparticles to which the Raman dye is attached, the Raman dye is based on SERS based on Raman. Measure the signal, a technique widely known in the art.

The "Raman 　 dye" can be used without limitation, as long as it is widely used in this technical field. Specific examples include rhodamine 6G, rhodamine B isothiocyanate (RBITC), adenine, 4-amino-pyrazole (3,4-d) pyrimidine, 2-fluoro adenine, N6-benzoyl adenine, kinetine , Dimethyl-allyl-amino-adenine, zeatin, bromo-adenine, 8-aza-adenine, 8-azaguanine, 6-mercaptopurine, 4-amino-6-mercaptopyrazolo (3,4 -d) pyrimidine, 8-mercaptoadenin, and 9-amino-acridine, but are not necessarily limited thereto.

In the present invention, the term "fusion protein nanocage having a peptide for inhibiting multivalent new angiogenesis" refers to a nanocage structure containing a fusion polypeptide including one or more peptides for inhibiting new angiogenesis. Specifically, a peptide that specifically binds to the Vascular Endothelial Growth Factor (VEGF) receptor (Flt1 or Flk-1/KDR) and a pigment epithelial-derived factor (PEDF) that is an angiogenesis inhibitor ) Means a nanostructure containing a fusion polypeptide containing all of them.

In the present invention, "fusion protein nanocage" is also referred to as "fusion protein cage".

The fusion polypeptide according to the present invention is schematically shown in FIG. 1.

The present invention introduces a specific class of stimulatory elastin-based polypeptides (EBPs) into ferritin nanostructures for non-chromatographic purification and exposure of therapeutic domains.

For a specific example, [anti-Flt1 peptide of SEQ ID NO: 3] is linked to the N-terminus of [helix-based polypeptide represented by SEQ ID NO: 1], and the helix-based polypeptide represented by SEQ ID NO: 1 At the other end, [Hydrophilic EBP]-[PEDF 34-mer of SEQ ID NO: 4]-[Hydrophilic EBP]-[Helix-based polypeptide represented by SEQ ID NO:2] were sequentially linked.

The present invention genetically engineered a fusion protein cage having a multivalent double angiogenesis inhibitory peptide to treat uncontrolled angiogenesis dependent diseases. The fusion polypeptide was composed of a helix base protein cage (HPC) for self-assembly, a heat sensitive EBP, and two types of anti-angiogenic peptides (Anti-Flt1 peptide and PEDF 34-mer peptide). HPC was derived from ferritin (SEQ ID NO: 2) consisting of four helical bundles (SEQ ID NO: 1) and relatively short spirals. Two different anti-angiogenic peptides were placed at the exposure sites of HPC and EBP, respectively, and introduced for effective exposure and non-chromatographic purification of the PEDF 34-mer peptide. Two EBP monoblocks were effectively fused between the PEDF 34-mer peptides to expose the PEDF 34-mer peptide. EBP-PEDF 34-mer-EBP triple-block copolypeptide is the 4th helix and 5th of HPC?? It was located between the spirals. The anti-Flt1 peptide was located at the N-terminus of the HPC, another site of exposure. The fusion polypeptide was self-assembled into a nanocage structure with a multivalent double angiogenesis inhibitory effect. We developed the application field of a fusion protein cage using the properties of VEGFR binding affinity of Anti-Flt1 peptide and iron storage and pH reactivity of HPC.

Cell imaging and sensing functions are added to the fusion protein by conjugating a fluorescent (Raman) dye to HPC and synthesizing gold nanoparticles (AuNP) inside the HPC for surface enhanced Raman scattering (SERS) based sensing. did. The fusion protein cage conjugated with a fluorescent dye was bound to a vascular endothelial growth factor receptor (VEGFR) at the cell membrane, and showed both angiogenesis inhibitory effect and cell imaging.

A fusion protein cage was developed as a SERS-based sensing probe by reducing the gold ions accumulated in HPC to AuNP and introducing Raman dye to the surface of AuNP. Raman dye penetrates when the fusion protein cage is released under acidic conditions and is introduced to the AuNP surface, and the cage structure is restored under neutral conditions. The self-assembly and aggregation of the fusion protein cage was confirmed by dynamic light scattering (DLS) over time. Both anti-angiogenesis and cellular imaging of the fusion protein were studied in vitro by human umbilical vein endothelial cells (HUVEC) investigations.

The therapeutic composition comprising the fusion polypeptide for inhibiting neovascularization of the present invention is a pharmaceutical composition. The pharmaceutical composition may contain the fusion polypeptide and may contain other substances that do not interfere with use for the purpose of inhibiting angiogenesis in vivo. These other substances are not limited and may include diluents, excipients, carriers and/or other angiogenesis inhibitory substances.

In some embodiments, the fusion polypeptide for inhibiting neovascularization of the present invention is formulated for routine human administration, for example by formulation with an appropriate diluent comprising sterile water and normal saline.

Administration or delivery of the therapeutic composition according to the present invention may be through any route as long as the target tissue is available through that route. For example, administration can be administered to a target tissue such as topical or intradermal, subcutaneous, intramuscular, intraperitoneal, intraarterial, coronary, intrathecal or intravenous injection, or intravitreal injection, etc. Tissue) by direct injection. The stability and/or potency of the fusion polypeptides disclosed herein allows for convenient routes of administration, including subcutaneous, intradermal, intravenous and intramuscular.

The present invention provides methods of delivering a fusion polypeptide to a cell (eg, as part of a composition or formulation described herein), and methods of treating, alleviating, or preventing the progression of a disease in a subject. As used herein, the term “subject” or “patient” refers to humans and other primates (eg chimpanzees and other ape and monkey species), farm animals (eg cows, sheep, pigs, goats and horses), Household mammals (e.g., dogs and cats), laboratory animals (e.g., rodents such as mice, rats and guinea pigs) and birds (e.g., domestic, wild and competitive use such as chickens, turkeys and poultry) Birds, ducks, geese, etc.), including, but not limited to, any vertebrate animal. In some embodiments, the subject is a mammal.

In another embodiment, the mammal is human.

The fusion polypeptide or pharmaceutical composition of the present invention may be contacted with a target cell (eg, a mammalian cell) in vitro or in vivo.

In another aspect, the present invention provides a method of treating or preventing a disease caused by angiogenesis, comprising administering to an individual the composition for treatment according to the present invention.

For clinical use, the fusion polypeptides of the present invention can be administered alone or formulated into a pharmaceutical composition via any suitable route of administration effective to achieve the desired therapeutic outcome. The “route” of administration of the oligonucleotides of the present invention will mean enteral, parenteral and topical administration or inhalation. The enteral route of administration of the fusion polypeptide of the present invention includes the oral cavity, the stomach, the intestines, and the rectum. Parenteral routes include ocular infusion, intravenous, intraperitoneal, intramuscular, intrathecal, subcutaneous, topical infusion, vaginal, topical, nasal, mucosal and pulmonary administration. The route of topical administration of the fusion polypeptides of the present invention refers to the external application of oligonucleotides into the epidermis, oral cavity and ear, eye and nose.

The therapeutic composition may be administered by parenteral, oral, transdermal, sustained release, controlled release, delayed release, suppository, catheter or sublingual administration.

The fusion polypeptide in the therapeutic composition can be administered in an amount of 15 mg/kg or less during intravenous injection when administered in combination with other drugs, and in an amount of 2.5 mg or less during intravitreal injection. Can be administered.

The invention is further illustrated by the following additional examples which should not be construed as limiting. It should be understood by those skilled in the art that, in view of the present invention, various changes to the specific embodiments disclosed may be possible and equivalent or similar results may be obtained without departing from the spirit and scope of the present invention.

Unless otherwise defined, all technical and scientific terms used in this specification have the same meaning as commonly understood by an expert skilled in the art to which the present invention belongs. In general, the nomenclature used in this specification is well known and commonly used in the art.

The self-assembled fusion protein cage having anti-angiogenic and neovascular cell imaging functions of the present invention treats angiogenesis-related diseases such as retina, cornea, choroidal neovascularization, tumor growth, cancer cell metastasis, diabetic retinopathy, and asthma. It presents a new path for advanced drug delivery systems.

1(A) amino acid sequences of anti-Flt1 peptide, PEDF 34-mer, and EBPP[A ₁ G ₄ I ₁ ] ₁ (B) and (C) anti-Flt1-HPC-EBPP[A ₁ G ₄ I _1] ] _12- PEDF 34-mer fusion polypeptide block design and application strategy. (B) (a) The anti-Flt1 peptide is located at the N-terminus and EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer-EBPP[A ₁ G ₄ I ₁ ] ₆ triple block is the fourth HPC , Located in the middle of the 5th spiral. (b) The self-assembled structure of the fusion polypeptide was modified for bioimaging and biosensing. Fluorescent dyes were labeled in the cage for bioimaging, gold nanoparticles were synthesized inside the cage structure, and conjugated with Raman dyes for biosensing. (C) The fusion protein cage was induced anti-angiogenic function by two mechanisms. Anti-Flt1 peptide inhibited intracellular angiogenesis signal, and PEDF 34-mer activated anti-angiogenic signal.
Figure 2 shows (a) HPC4-EBPP[A ₁ G ₄ I ₁ ] ₁₂ -HPC5, (b) anti-Flt1-HPC4-EBPP [A ₁ G ₄ I ₁ ] ₁₂ -HPC5, (c) HPC4- EBPP [A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5, and (d) anti-Flt1-HPC4- EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF (A) Agarose gel (1%) and (B) SDS-PAGE gel images of 34-mer-EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5. (A) The modified pET21-a(+) plasmid encoding the fusion protein was treated with Xba I and AcuI restriction enzymes. The length of the gene segment containing the fusion protein cage was labeled under the gene segment. (B) The fusion protein cage was expressed in E. coli and purified by ITC. The gel was visualized by copper staining. The expected molecular weight is presented below the band.
3 shows (a) HPC4-EBPP[A ₁ G ₄ I ₁ ] ₁₂ -HPC5, (b) anti-Flt1-HPC4-EBPP [A ₁ G ₄ I ₁ ] ₁₂ -HPC5, (c) HPC4- EBPP [A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer-EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5, and (d) anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF Thermal sensitivity of 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5. 25 μM in 0.01 M PBS (a) HPC4-EBPP[A ₁ G ₄ I ₁ ] ₁₂ -HPC5, (b) anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₁₂ -HPC5, (c) HPC4 -EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5, and (d) anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ (A) Turbidity profile and (B) hydrodynamic radius of -HPC5. The absorbance and hydrodynamic radius at 350 nm were measured while heating at 1 °C/min.
Figure 4 shows (A) fluorescence microscopy images and 0.01 nM-10 uM of (a) HPC4-EBPP[A ₁ G ₄ I ₁ ] ₁₂ -HPC5, (b) anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₁₂ -HPC5, (c) HPC4- EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5, and (d) anti-Flt1-HPC4 -EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5-treated (B) calcein-AM-labeled HUVECs tube formation degree . This was quantified from the (A) image.
Figure 5 shows (A) anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer-EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5 conjugated fluorescent dye in SDS-PAGE. Visualization. (a) Anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -SDS stained in copper solution of HPC5 before conjugation with fluorescent dye PAGE of the gel and (b) the appearance of the gel after irradiation with a fluorescent dye and exposure to UV light under a fluorescent scanner. (B) (a) anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5 and (b) fluorescent dye conjugated Fluorescence spectrum of anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5. (C) 1 or 10 nM dye conjugation anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer-EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5 is 15, 30, And HUVEC fluorescence images processed for 60 minutes and merged images of bright field. In (C), the size bar is 200 um.
Figure 6 shows (A) hydrodynamic radius and (B) (a) before gold ion treatment, (b) after gold seed synthesis and (c) anti-Flt1-HPC4-EBPP[A ₁ G ₄ I] in gold nanoparticle growth. ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ Ultraviolet absorption spectrum of -HPC5. (C) TEM image of gold nanoparticles inside the fusion protein cage. (D) Raman spectra of gold nanoparticles conjugated with Raman dye in a fusion protein cage.

Example 1: Materials

pET-21a (+) vector and BL21 (DE3) E. Coli cells were manufactured by Novagen Inc. (Madison, WI, US) products were used. Top 10 competent cells and Calcein-AM were purchased from Invitrogen (Carlsbad, CA, US), and HUVECs were purchased from Lonza (Basel, Switzerland). All custom-made oligonucleotides were synthesized by Cosmo Gene Tech (Seoul, South Korea), and human recombinant VEGF-165 (rhVEGF ₁₆₅ ) was used by R&D SYSTEMS (Minneapolis, US). CIP (Calf intestinal alkaline phosphatase), BamHI and XbaI were manufactured by Thermo Fisher Scientific (Waltham, Massachusetts, US). AcuI and BseRI were purchased from New England Biolabs (Ipswich, MA, US). T4 DNA ligase was used by Elpis Bio-tech (Taejeon, South Korea). DNA miniprep, gel extraction, and PCR purification kits were manufactured by Geneall Biotechnology (Seoul, South Korea). Dyne Agarose High is owned by DYNE BIO, Inc. (Seongnam, South Korea) products were used. Top 10 cells are manufactured by MO BIO Laboratories, Inc. It was cultured in TB DRY media purchased from (Carlsbad. CA, US). BL21(DE3) cells were cultured in Circle Grow media purchased from MP Biomedicals (Solon, OH, US). HUVECs were raised in EGM-2 Bullet Kit and EBM-2 purchased from Lonza (Basel, Switzerland). The Ready Gels, Tris-HCl 2-20% precast gels were purchased from Bio-Rad (Hercules, CA, US). PBS (phosphate buffered saline, pH 7.4) and ampicillin were manufactured by Sigma-Aldrich (St Louis, MO, US). Matrigel was purchased from BD Biosciences (San Diego, CA, US). Human recombinant VEGF ₁₆₅ protein and human recombinant VEGF R1/Flt-1 F _c were purchased from R&D System (Minneapolis, MN, US). Gold(III) chloride trihydrate, sodium borohydride, ascorbic acid, and malachite Green isothiocyanate were purchased from Sigma-Aldrich (St Louis, MO, US).

Example 2: Marking of different EBP blocks and their block polypeptides

Different EBPs having the pentapeptide repeating unit Val-Pro-(Gly or Ala)-X _aa- Gly[VP(G or A)XG] are named as follows. X _aa may be any amino acid except Pro. First, the pentapeptide repeat of Val-Pro-Ala-X _aa- Gly (VPAXG) with plasticity is defined as an elastin-based polypeptide with plasticity (EBPP). Meanwhile, the pentapeptide repeat of Val-Pro-Gly-X _aa- Gly (VPGXG) is called the elastin-based polypeptide with elasticity (EBPE). Second, in [X _i Y _j Z _k ] _n , the capital letters in parentheses are the single letter amino acid code of the guest residue, that is, the amino acid at the 4th position (X _aa or X) of the EBP pentapeptide, and the corresponding lower The subscript indicates the ratio of the guest residues of the EBP monomer gene as a repeating unit. The number of subscripts n of [X _i Y _j Z _k ] _n (i+j+k=6) is the repetition of the EBP of [VPGXG VPGXG VPGXG VPGXG VPGXG VPGXG] or [VPAXG VPAXG VPAXG VPAXG VPAXG VPAXG], the EBP of the present invention Shows the total number of times. For example, EBPP[A ₁ G ₄ I ₁ ] ₆ is an EBPP block consisting of 6 repeats of units of [VPAXG VPAXG VPAXG VPAXG VPAXG VPAXG], where Ala, Gly at the 4th guest residue position (X _aa ) And the ratio of Ile is 1:4:1. Finally, the diblock polypeptides of EBPP and other peptides are named according to the configuration of each block in square brackets with a hyphen between blocks, such as EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5.

Example 3: Preparation of a modified pET-21a vector for seamless gene cloning

The pET-21a vector was treated with XbaI, BamHI and CIP in FastDigest buffer at 37° C. for 20 minutes, followed by dephosphorylation. Restriction enzyme-treated plasmid DNA was purified using a PCR purification kit, and eluted with deionized water. Two compatible oligonucleotides containing the sticky ends of XbaI and BamHI were designed as follows.

5′-ctagaaataattttgtttaactttaagaaggaggagtacatatgggctactgataatgatcttcag-3′ (SEQ ID NO: 19)

5′-gatcctgaagatcattatcagtagcccatatgtactcctccttcttaaagttaaacaaaattattt-3′ (SEQ ID NO: 20)

The two oligonucleotides were annealed by heating at 95° C. for 2 minutes in T4 DNA ligase buffer, and then slowly cooled at room temperature for 3 hours. The annealed double-stranded DNA (dsDNA) and the linearized vector are treated with T4 DNA ligase in T4 DNA ligase buffer and incubated at 37°C for 30 minutes to place the DNA transgene into the multiple cloning site (MCS) of pET-21a vector (insert) was ligated. For complete cloning and expression, the recombinant pET-21a (mpET-21a) vector was transformed into Top10 competent cells, and then 50 μg/ml of ampicillin was treated SOC (super optimal broth). with catabolite repression) on the plate. The DNA sequence of the mpET-21a vector was verified by fluorescent dye terminator DNA sequencing (Applied Biosystems Automatic DNA Sequencer ABI 3730).

Example 4: Synthesis of EBP gene unit and oligomerization thereof

The EBPP sequence containing Val-Pro-Ala -X _aa -Gly, which is a'pentapeptide repeating unit' in a ratio of 1:4:1 as the fourth residue, Ala, Gly, and Ile, is T _t lower than the physiological temperature. It is designed to optimize. A pair of oligonucleotides for encoding EBPP[A ₁ G ₄ I ₁ ] ₁ in T4 DNA ligase buffer was annealed by heating at 95° C. for 3 minutes, and then slowly cooled at room temperature for 3 hours. The mpET-21a cloning vector was subjected to BseRI and CIP treatment at 37° C. for 30 minutes and dephosphorylated. Restriction enzyme-treated plasmid DNA was purified using a PCR purification kit, and eluted with deionized water. The annealed dsDNA and the linearized mpET-21a cloning vector were ligated by treatment with T4 DNA ligase in T4 DNA ligase buffer and incubation at 16° C. for 30 minutes. The ligated plasmid was transformed into Top10 chemical competent cells, and then plated on SOC plates treated with 50 μg/ml of ampicillin. The DNA sequence was confirmed through DNA sequencing. Genes were constructed until the number of repetitions was 6, that is, EBPP[A ₁ G ₄ I ₁ ] ₆ .

The EBP sequence having Val-Pro-(Gly or Ala)-X _aa- Gly, which is a pentapeptide repeating unit in which the fourth residues are varied at different molar ratios, was designed at the DNA level to optimize T _t below physiological temperature. Table 1 shows the amino acid sequences of EBPs having various pentapeptide repeat units.

[Table 1] EBP amino acid sequence

Example 5: Preparation of PEDF 34-mer coding gene in cloning vector by PCR

The PEDF cDNA fragment 34-mer (130-231) was amplified from human PEDF cDNA fragments by PCR with the following primers.

5'-AAAGGATCCCCCTACTGGTAATGCTCTTCAGTCTAGAGAT-3' (forward) (SEQ ID NO: 21)

5'-CACGACCAACGGCTACTGATAGTGATCTTCAGCTAGCGAT-3' (reverse) (SEQ ID NO: 22)

The forward primer had an XbaI restriction site at the 3'end, and the reverse primer had a NheI restriction site at the 5'end. Both primers had an AcuI restriction enzyme and a recognition site in the middle for smooth cloning of the gene containing EBPP[A ₁ G ₄ I ₁ ] _n . The amplified gene fragment of PEDF 34-mer was treated with XbaI and NheI in CutSmart buffer at 37° C. for 2 hours to generate the transgene. After treatment, the product was electrophoresed on an agarose gel, and the inserted gene was purified using a gel extraction kit. The pET-21a cloning vector was treated with XbaI and CIP at 37° C. for 1 hour, followed by dephosphorylation. Restriction enzyme-treated DNA was purified using a PCR purification kit and eluted with deionized water. The restriction enzyme-treated PEDF 34-mer gene fragment and the linearized pET-21a cloning vector were ligated by treatment with T4 DNA ligase in T4 DNA ligase buffer and incubation at 16° C. for 30 minutes. The ligated product was transformed into Top10 chemical competent cells, and plated on SOC plates treated with 50 μg/mL of ampicillin. Transformants were initially screened on agarose gels by diagnostic restriction enzyme treatment, and further confirmed by the aforementioned DNA sequencing.

Example 6: HPC (helix-based protein cage) encoding gene production from cloning vector

In order to fuse with genes of other peptides between the helical bundle (ferritin A, B, C, D) and the short fifth helix (ferritin E), mPET the gene encoding the 4 helical bundles and the gene encoding the 5th helix. Cloned to -21a. Genes encoding four helical bundles with XbaI and BamHI restriction sites at both ends were transferred to the pUCIDT vector. Plasmids containing four helical bundles were treated with 10 U of XbaI and 10 U of BamHI in CutSmart buffer at 37° C. for 2 hours to generate the transgene. After treatment, the product was electrophoresed on an agarose gel, and the inserted gene was purified using a gel extraction kit. A total of 4 μg of mpET-21a cloning vector was treated with restriction enzymes, and dephosphorylated at 37°C for 1 hour with 15 U of XbaI, 10 U of BamHI and 10 U of FastAP thermosensitive alkaline phosphatase. did. Plasmid DNA was purified using a PCR purification kit, and eluted in 40 μL of distilled and deionized water. 90 pmol of four helical bundle gene fragments and 30 pmol of linearized mpET-21a cloning vector were ligated by treatment with 1U of T4 DNA ligase together in T4 DNA buffer and incubation at 16° C. for 30 minutes. The ligated product was transformed into Top10 competent cells, and plated on SOC plates treated with 50 μg/mL of ampicillin. Transformants were initially screened on agarose gels by diagnostic restriction enzyme treatment, and were further identified by the aforementioned DNA sequencing 5 with sticky ends of GG-5' and 3'-CC. The 57bp-sized gene encoding the first helix was constructed through hybridization. A pair of oligonucleotides encoding the fifth helix was heated at 95° C. for 3 minutes in a T4 DNA ligase buffer to a concentration of 50 μL of 2 μM oligonucleotides, and then slowly cooled at room temperature for 3 hours or more. A total of 4 μg of mpET-21a cloning vector was treated, and dephosphorylated with 15 U of BseRI and 10 U of FastAP as a thermosensitive alkaline phosphatase at 37° C. for 30 minutes. After the plasmid DNA was purified using a PCR purification kit, it was eluted with 40 μL of distilled water and deionized water. 90 pmol of the annealed double-stranded DNA (dsDNA) and 30 pmol of the linearized mpET-21a cloning vector were ligated by treatment with 1U of T4 DNA ligase in T4 DNA buffer and incubation at 16° C. for 30 minutes. The ligated plasmid was transformed into Top 10 chemical competent cells, and then plated on SOC plates treated with 50 μg/mL of ampicillin. DNA sequence was confirmed by DNA sequencing.

Example 7: Gene production of anti-Flt1-HPC4-EBP-PEDF 34-mer-HPC5 fusion protein cage

A pair of oligonucleotides encoding an anti-Flt1 peptide that acts as an antagonist of VEGFR1 was chemically synthesized by Cosmo Genetech (Seoul, Korea), and an oligonucleotide cassette with a binding portion of AcuI and BseRI It was annealed so that it might become. Oligonucleotide cassettes encoding anti-Flt1 peptides for seamless cloning were reasonably designed without BseRI, XbaI, AcuI and BamHI recognition sites. Each plasmid and oligonucleotide including EBPP[A ₁ G ₄ I ₁ ] ₆ , PEDF 34-mer, 4 helical bundle fragments of HPC and 5 helical fragments of HPC with recognition sites for BseRI, XbaI, AcuI and BamHI Cassettes consist of anti-Flt1- 4 helical bundles (HPC4)-EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer-EBPP[A ₁ G ₄ I ₁ ] ₆ -5 helical fusion poly(HPC5) It was used to create genes for peptide libraries. To encode the fusion polypeptide library, number 5?? The plasmid vector encoding the helix was treated with 15 U of BseRI at 37° C. for 1 hour in CutSmart buffer. Restriction enzyme-treated plasmid DNA was purified using a PCR purification kit, and dephosphorylated by treatment with 10 U FastAP as heat-sensitive alkaline phosphatase in CutSmart buffer at 37° C. for 1 hour. Restriction enzyme-treated and dephosphorylated plasmid DNA was purified using a PCR purification kit, and eluted with 40 μL of distilled and deionized water. For the production of the inserted gene, 4 mg of EBPP[A ₁ G ₄ I ₁ ] ₆ gene was treated with 10 U of BseRI and 15 U of AcuI for 1 hour at 37° C. in CutSmart buffer. After treatment, the product was electrophoresed on an agarose gel, and the inserted gene was purified using a gel extraction kit. 90 pmol of the purified insert gene and 30 pmol of the linearized vector were ligated by treatment with 1 U of T4 DNA ligase in T4 DNA ligase buffer and incubation at 16° C. for 30 minutes. The ligated product was transformed into Top10 chemical competent cells and plated on SOC plates treated with 50 μg/mL of ampicillin. Transformants were initially screened on agarose gels by diagnostic restriction enzyme treatment, and further confirmed by DNA sequencing. A plasmid vector containing the inserted DNA was constructed through the above method. For the production of the inserted gene, PEDF 34-mer was prepared through PCR and restriction enzyme treatment as described above, and an oligonucleotide cassette encoding the anti-Flt1 peptide was used as the insertion gene. The four helical bundles of the inserted genes were constructed in the same way with the EBPP[A ₁ G ₄ I ₁ ] ₆ transgene. The ligation proceeded as described above.

Example 8: Gene expression and purification of EBPs and fusion protein cage

Each vector including EBPs and fusion protein cages was transformed into E. coli strain BL21(DE3) cells, and then inoculated into 50 mL of CircleGrow media treated with 50 μg/mL ampicillin. Preculture was performed overnight at 200 rpm at 37°C in a shaking incubator. Thereafter, 50 ml of TB DRY media was inoculated into 500 ml of CircleGrow media treated with 50 μg/mL ampicillin, and incubated for 16 hours at 37° C. at 200 rpm in a shaking incubator. When the optical density (OD ₆₀₀ ) reached 1.0 at 600 nm, the over-expression of the polypeptide was induced by adding IPTG to a final 1 mM. Cells were centrifuged for 10 minutes at 4° C. at 4500 rpm. The expressed EBPs and their block polypeptides were purified using ITC as described above. Cell pellets containing EBPs were resuspended in 30 mL of PBS buffer, and EBPs were purified under PBS conditions. The cell pellet containing the fusion protein cage was resuspended in 30 mL of PBS to which 3 M urea was added, and purified in PBS to which 3 M urea was added to denature the helical structure of NPC. The cells were sonicated for 10 seconds (VC-505, Sonic and materials Inc, Danbury, CT), and then the cells were lysed in an ice bath while resting for 20 seconds. The cell lysate was placed in a 50 mL centrifuge tube and centrifuged at 13000 rpm for 15 minutes at 4° C. in order to precipitate insoluble debris. The supernatant containing the dissolved EBPs was placed in a new 50 mL centrifuge tube, and centrifuged for 15 minutes at 4° C. at 13000 rpm with PEI 0.5% w/v to precipitate nucleic acid contaminants. The inverse phase transition of EBPs was induced by adding NaCl to a final concentration of 3 M, and the agglomerated EBPs were separated from the solution by centrifugation at 13000 rpm for 15 minutes at 4°C. Aggregated EBPs were resuspended in cold buffer and centrifuged at 13000 rpm for 15 minutes at 4° C. to remove aggregated protein contaminants. This aggregation and resuspension process was repeated 5-10 times until the purity of EBP reached about 95% as determined by SDS-PAGE.

1 is a block diagram of the anti-peptide -Flt1, PEDF 34-mer peptides, and _{EBPP [A 1 G 4 I 1} ] 1 in amino acid _{sequence, EBPP [A 1 G 4 I} 1] 12 -PEDF 34-mer fusion polypeptide Design The anti-angiogenic function according to the two mechanisms of self-assembly, the self-assembly structure for bioimaging and biosensing, and the self-assembled fusion protein cage are shown. The amino acid sequence of HPC (SEQ ID NO: 1 and 2), anti-Flt1 peptide (SEQ ID NO: 3), PEDF 34-mer peptide (SEQ ID NO: 4), EBPP[A ₁ G ₄ I ₁ ] (SEQ ID NO: 6), is in Table 2 and Fig. 1(A).

[Table 2]

Figure 1(B) is a block design of (a) anti-Flt1-HPC-EBPP[A ₁ G ₄ I ₁ ] _12- PEDF 34-mer fusion polypeptide and (b) self-assembly structure, by fluorescent dye conjugation. A strategy for the modification of the structure, and the synthesis of Raman dyes conjugated to gold nanoparticles (AuNPs) for bioimaging and biosensing is shown. HPC consists of four spiral bundles (hereinafter referred to as'HPC4') and relatively short spirals (alpha-helix, hereinafter referred to as'HPC5'), which are self-assembled into a nanocage, and the N-terminal and There is an exposed area between the 4th and 5th helix respectively. Two anti-angiogenic peptides (anti-Flt1 peptide and PEDF 34-mer peptide) were fused to each exposed site of HPC. The anti-Flt1 peptide was located at the N-terminus of HPC, and EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer-EBPP[A ₁ G ₄ I ₁ ] ₆ is the 4th??, of the 5th helix. Was located between. The EBP block was introduced to effectively expose the PEDF 34-mer peptide and to purify the fusion polypeptide by a non-chromatographic method. The fusion protein cage was conjugated with a fluorescent dye by a thiol-maleimide reaction in cysteine. For surface-enhanced Raman scattering (SERS)-based applications, AuNPs were synthesized by accumulation and reduction of gold ions inside the HPC structure. The AuNP-containing structures were partially destroyed to introduce the Raman dye to the AuNP surface, and their original structure was restored. For anti-angiogenic function, the fusion polypeptide consisted of anti-Flt1 peptide and PEDF 34-mer with different mechanisms for anti-angiogenesis (Fig. 1(C)). The anti-Flt1 peptide inhibited intracellular angiogenesis signal by binding to VEGFR1 (Flt1) and interfered with the interaction between VEGF and VEGFR1. PEDF 34-mer, the anti-angiogenic functional region of PEDF, triggered intracellular anti-angiogenic signals. In order to study the anti-angiogenic function of the fusion protein cage according to the anti-Flt1 peptide and PEDF 34-mer, four kinds of fusion polypeptides, anti-Flt1 peptides and fusion polypeptides without PEDF 34-mer, anti-Flt1 A fusion polypeptide comprising a peptide or PEDF 34-mer, and a fusion polypeptide comprising an anti-Flt1 peptide and PEDF 34-mer have been designed.

Example 9: Characterization of EBPs and anti-Flt1-HPC4-EBP-PEDF 34-mer-HPC5 fusion protein cage

The purity of EBPs and fusion protein cages was determined by SDS-PAGE. The effect of temperature on the reverse phase transition of 25 μM EBPs and fusion protein cages in PBS was 10 to 85°C, 1°C/min at a multi-cell thermoelectric temperature controller (Varian Instruments, Walnut Creek, CA). ) And the OD ₃₅₀ was measured using a Cary 100 Bio UV/Vis spectrometer. The self-assembly of the fusion protein cage into the cage structure and the thermal sensitivity of the cage structure were confirmed with a temperature-controlled Nano ZS90 (ZEN3690) dynamic light scattering (DLS) equipment (Malvern instruments, Worcestershire, UK). Their hydrodynamic radius (R _H ) in 25 μM PBS was measured 11 times at each temperature at a temperature of 20 to 60° C. and a heating rate of 1° C./min in 25 μM PBS. Their T _t was identified as the starting temperature of the phase transition, and was calculated by each DLS plot.

Example 10: of HUVECs using a fusion protein cage In vitro Tube formation investigation

In vitro tube formation assay of HUVECs using fusion protein cages was performed to evaluate their effects on endothelial cell growth (proliferation), migration (migration) and tube formation. In order to coat 200 μL of Matrigel on a 48-well plate, the Matrigel was solidified by incubating at 37°C for 30 minutes. For fluorescent labeling, HUVECs were incubated in 0.5 μM calcein-AM for 15 minutes at 37°C. To measure how the growth, migration and tube formation of endothelial cells are stimulated, 4 Х 10 ⁴ cells/well of calcein-labeled HUVECs were sprinkled on matrigel-coated wells, at 37° C., at different concentrations for 4 hours. Incubated with ng/ml human recombinant rhVEGF ₁₆₅ and fusion protein cage. The tube formation of HUVECs was photographed under a micromanipulator (ZEISS, Oberkochen, Germany) and was quantified by measuring the total tube length of three random zones per well with a neovascularization analyzer of Image J lab software. Their tube formation was performed in three replicates.

Example 11: HUVEC imaging using fluorescent dye conjugated to a fusion protein cage

The fusion protein cage was labeled with Alexa Fluor 488 C5 maleimide for cell imaging in vitro . The 50 uM fusion protein cage was incubated in 0.01 M PBS containing 3 M urea and 10 mM DTT for 2 hours at room temperature with 500 uM Alexa Fluor C5 maleimide. The remaining maleimide 488 C5 maleimide was removed by dialysis against PBS. Labels were characterized on SDS-PAGE without staining with fluorescence spectra (Ex: 480; Em: 500-550, Ex slit 10 nm; Em slit 5 nm) and fluorescent protein. HUVECs were sprayed onto 48 well plates at 4 Х 10 ⁴ cells/well and incubated overnight. HUVECs were incubated with 50 ng/ml human recombinant rhVEGF ₁₆₅ and dye conjugated fusion protein cages at 37° C. at different concentrations every 15, 30, and 60 minutes. HUVECs were photographed in the bright field of a micromanipulator (ZEISS, Oberkochen, Germany) and fluorescence of FITC.

Example 12: Synthesis of gold nanoparticles in the cage structure of a fusion protein cage and a Raman dye conjugated to gold nanoparticles

A 25 uM fusion protein cage was incubated with 0.2 mM HAuCl ₄ at room temperature for 3 hours in 0.01 M PBS, washed twice with PBS to remove unbound HAuCl ₄ with a centrifuge from which glycerol was removed from the surface. Gold ions were removed by adding 1 mM NaBH ₄ to the gold seed. At this time, the solution was pale-yellow. After water quench for 3 hours, 0.2 mM HAuCl ₄ was additionally treated and incubated for 1 hour. 1 mM ascorbic acid was added to grow gold seeds into gold nanoparticles (AuNPs). At this time, the final solution was ruby red. The nanoparticles synthesized inside the protein cage were characterized by measuring absorbance and TEM images at 350-900 nm.

For Raman dyes conjugated to gold nanoparticles (AuNPs) within the protein cage structure, the pH of 0.01 M PBS buffer containing AuNP-protein decreased to pH 6.0, which is lower than the pI of 6.029 of the fusion protein as HCl was added. did. 10 uM MGITC was added to a 0.01M PBS buffer at pH 6.0, and the pH of the buffer increased to 7.4 by adding NaOH after 1 hour incubation. Raman measurements were performed using a Raman spectroscope (Renishaw 2000, Renishaw, UK).

result

The fusion protein cage composed of anti-Flt1-peptide, PEDF 34-mer, and EBP was constructed by cloning the gene encoding the fusion protein cage and overexpression of the fusion protein cage by IPTG induction. The gene encoding the fusion protein cage is EBPP[A ₁ G ₄ I ₁ ] ₆ , PEDF 34-mer, the four helices of HPC, and the gene encoding the anti-Flt1 peptide in a plasmid containing the fifth helix of HPC. It was made by sequentially inserting. Insertion of each gene was confirmed by XbaI and AcuI restriction enzyme treatment, agarose gel electrophoresis, and DNA sequencing. Genes encoding the prepared four types of fusion protein cages, (a) HPC4-EBPP[A ₁ G ₄ I ₁ ] ₁₂ -HPC5, (b) anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₁₂ -HPC5, (c) HPC4- EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5, and (d) anti-Flt1-HPC4- EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5 is shown in Fig. 2(A). The genes encoding the fusion protein cage were treated with XbaI and AcuI, and the lengths of these DNA fragments were labeled for each gene on an agarose gel. (a) HPC4-EBPP[A ₁ G ₄ I ₁ ] ₁₂ -HPC5-HPC5, (b) anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₁₂ -HPC5, (c) HPC4- EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5, and (d) anti-Flt1-HPC4- EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34- The DNA lengths of each gene encoding mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5 were 1614, 1632, 1719, and 1737 bp, respectively. Since the XbaI restriction site was present in the gene of the fusion protein cage, the length of the DNA fragments labeled for each gene on the agarose gel was 37bp, which is larger than the original gene.

The fusion protein cage was expressed in E. coli and purified by reverse transfer cycle (ITC). The purity and molecular weight of the purified fusion protein cage were confirmed by SDS-PAGE stained with copper to visualize the protein band (Fig. 2(B)). (a) HPC4-EBPP[A ₁ G ₄ I ₁ ] ₁₂ -HPC5, (b) anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₁₂ -HPC5, (c) HPC4- EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5, and (d) anti-Flt1-HPC4- EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- The expected molecular weight of EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5 is shown in the bands below (48.6, 49.4, 52.4, and 53.1 kDa (left to right)) and the rightmost lane of the SDS-PAGE gel is the standard protein. Shows the movement of the size marker. Compared to the standard protein size marker and the theoretical molecular weight, the movement of the fusion protein cage did not match the movement of the protein standard marker. The four types of fusion protein cages moved more than the theoretical molecular weight, and anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₁₂ -HPC5 was HPC4- EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34- mer- EBPP[A ₁ G ₄ I ₁ ] ₆ is located higher than -HPC5. It has been previously reported that EBP shifted about 20% more than the theoretical molecular weight on SDS-PAGE (McPherson, DT; Xu, J.; Urry, DW Protein Expression Purif. 1996, 7 (1), 51) -7.; Meyer, DE; Chilkoti, A. Biomacromolecules 2002, 3 (2), 357-367.; McDaniel, JR; MacKay, JA; Quiroz, FG; Chilkoti, A. Biomacromolecules 2010, 11 (4), 944 -952.). Anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₁₂ -HPC5 is EBPP[A ₁ G ₄ I ₁ ] ₆ Two-block HPC4-EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer -EBPP[A ₁ G ₄ I ₁ ] ₆ -Since it has a longer EBP block than -HPC5, anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₁₂ -HPC5 is HPC4-EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ It was located higher than -HPC5.

The thermal sensitivity of the fusion protein cage was characterized to observe the phase transition by measuring the absorbance of the polypeptide solution with increasing temperature. Turbidity profiles were prepared by measuring the absorbance of a 25 μM fusion protein cage at 350 nm in 10 mM PBS while heating at 1 °C/min (Figure 3(A)). The phase transition temperature (T _t ) was identified as an inflection point of each thermal plot shown in FIG. 3(A), and is summarized in Table 3.

[Table 3]

The turbidity at T _t is due to the self-assembled cage structure of the fusion protein cage, and the absorbance increased at a temperature above T _t . HPC4-EBPP[A ₁ G ₄ I ₁ ] ₁₂ -HPC5, anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₁₂ -HPC5, HPC4- EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34- mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5, and anti-Flt1-HPC4- EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5 The T _t of were 55.12, 52.24, 44.17, and 44.37°C, respectively. Wherein _{-Flt1-HPC4-EBPP [A 1} G 4 I 1] 12 -HPC5 is _{HPC4-EBPP [A 1 G 4} I 1] decreased 2.85 ℃ than ₁₂ -HPC5 _{T t.} However, HPC4- EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5 and anti-Flt1-HPC4- EBPP[A ₁ G ₄ I ₁ ] _6- The T _t of PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5 showed no significant difference. The fusion protein cage with PEDF 34-mer had a lower T _t than the fusion protein cage without PEDF 34-mer. HPC4- EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5 and anti-Flt1-HPC4- EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34 -mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5 is a combination of HPC4-EBPP[A ₁ G ₄ I ₁ ] ₁₂ -HPC5 and anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₁₂ -HPC5. It was 10.85 °C and 7.90 °C lower than the T _t , respectively. HPC4- EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5 and anti-Flt1-HPC4- EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34 -mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5 has triple-block EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer-EBPP[A ₁ G ₄ I ₁ ] ₆ and has anti-Flt1 -HPC4-EBPP[A ₁ G ₄ I ₁ ] ₁₂ -HPC5 had a single block of EBPP[A ₁ G ₄ I ₁ ] ₁₂ . Even if the EBP length of the fusion protein cage is the same, the number of EBP blocks of the triple block EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer-EBPP[A ₁ G ₄ I ₁ ] ₆ of the single block EBPP[ A ₁ G ₄ I ₁ ] 2 times more than ₁₂ . As the EBP block was split and PEDF 34-mer was inserted, the T _t of the fusion polypeptide decreased.

HPC-based fusion protein was assembled cage itself to the cage structure at a temperature below T _t, aggregation was at a temperature above T _t. Their self-assembly and aggregation were characterized by dynamic light scattering (DLS). The hydrodynamic radius (R _H ) of the 25 μM fusion protein cage in 10 mM PBS was measured 11 times at each temperature at a heating rate of 1° C./min in a temperature range of 25 to 60° C. Their T _t was identified as the inflection point of each thermal plot in Fig. 3(B) and is summarized in Table 2. HPC4-EBPP[A ₁ G ₄ I ₁ ] ₁₂ -HPC5, anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₁₂ -HPC5, HPC4- EBPP[A ₁ G ₄ I ₁ ] at a temperature lower than T _t ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5, and anti-Flt1-HPC4- EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ The R _H of I ₁ ] ₆ -HPC5 were 20.97, 26.27, 42.90, and 28.93 nm, respectively. The previously reported self-assembled cage structure had a radius of 12 nm. The R _H of the fusion protein cage was found to be larger than the reported size of the HPC cage structure due to the EBP at the exposed site. The size of the soluble unmer EBP was reported to be about 10 nm. The measured R _H of the fusion protein cage structure was greater than 20 nm, which is consistent with the expected R _H (16-nm) of the self-assembled cage structure with soluble EBP. At temperatures above T _t , their R _H instantaneously increased above 1000 nm, the value of aggregation. Fusion protein was assembled cage woman at a temperature lower than T _t, the result was aggregated at a temperature above T _t is turbidity corresponds to the profile results.

The anti-angiogenic function of the fusion protein cage was studied by investigating the cell migration and tube formation of HUVECs in vitro . To study the cell migration and tube formation inhibitory effects of HUVECs, fusion protein cages were treated at different concentrations for 4 hours in Matrigel with 50 ng/ml of human recombinant VEGF-165 (rhVEGF165) added to calcein-labeled HUVECs. did. To evaluate the relationship between each angiogenesis inhibitory peptide (anti-Flt1 peptide and PEDF 34-mer) and concentration, 0.01 nM, 0.1 nM, 1 nM, 10 nM, 0.1 uM, 1 uM, and 1 uM of HPC4 -EBPP[A ₁ G ₄ I ₁ ] ₁₂ -HPC5-excluded fusion protein cages were incubated with HUVECs. As a control, HPC4-EBPP[A ₁ G ₄ I ₁ ] ₁₂ -HPC5 without angiogenesis inhibitory peptide was treated with HUVECs at four concentrations (0.01 nM, 1 nM, 0.1 uM). The inhibition of tube formation of HUVECs in each condition is shown in Fig. 4(A), and the quantified inhibitory effect of each fusion protein cage is shown in Fig. 4(B) calculated from the tube length of HUVECs in the fluorescence image of Fig. 4(A). Was shown. The tube length of HUVECs cultured in a medium without other treatments was set to 0%, and the tube length of HUVECs treated with rhVEGF165 was set to 100% to induce cell migration and tube formation, and the tube length at each concentration was normalized. did.

_{HPC4-EBPP [A 1 G 4} I 1] HUVECs treated with ₁₂ -HPC5 is _{HPC4-EBPP [A 1 G 4} I 1] that, regardless of the concentration of ₁₂ -HPC5, similar to that of the HUVECs with the tube length and the culture rhVEGF165 Showed results. This means that HPC4-EBPP[A ₁ G ₄ I ₁ ] ₁₂ -HPC5 has no effect on tube formation of HUVECs. Except for HPC4-EBPP[A ₁ G ₄ I ₁ ] ₁₂ -HPC5, the other three fusion protein cages showed inhibitory effects in a wide range of concentrations. Wherein _{-Flt1-HPC4-EBPP [A 1} G 4 I 1] Tube formation of HUVECs incubated with ₁₂ -HPC5 anti _{-Flt1-HPC4-EBPP [A 1} G 4 I 1] 100 nM concentration of ₁₂ -HPC5 -Decreased with increasing to 1 uM range. HPC4- EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5 is anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₁₂ -HPC5 is Tube formation of HUVECs was inhibited in the concentration range of 0.01 nM-0.1 nM, which had no effect on HUVECs tube formation. HUVECs treated with 1 nM anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5 showed the lowest tube formation, and their tubes Formation decreased as the concentration of anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5 increased to 0.01 nM-1 nM. . Anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5 effectively forms HUVECs tubes in a wide range of concentrations in the present invention Inhibited. When the concentration of the fusion protein cage was higher than the effective concentration range, the HUVECs treated with the fusion protein cage containing the PEDF 34-mer peptide showed a degree of tube formation similar to that of the HUVECs cultured with rhVEGF165. In a previous report, PEDF 34-mer peptide was used to inhibit the transformation of basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF), and inactivation of nuclear factor of activated T cells (NFAT) and JNK (c- jun N-terminal kinase) inhibited the expression of endogenous caspase inhibitors and c-FLIP (FLICE-like inhibitory protein), thereby inducing angiogenesis. On the other hand, JNK has been reported as a positive regulator of angiogenesis in endothelial cells (EC). Inhibition of JNK dilutes sprout growth of EC in 3D capillary sprout culture, reduces cell growth and migration of EC, and is a gene regulator involved in cell growth and migration. The protein level of the transcription factor Egr-1 was reduced. This report provides an explanation for why fusion protein cages containing PEDF 34-mer are ineffective at higher concentrations in the investigation of HUVECs tube formation.

Anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer-EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5, which showed the most effective anti-angiogenic function, is an imaging probe. ) As a fluorescent dye. The maleimide-modified fluorescent dye was conjugated to thiol in HPC, and the conjugation of the fluorescent dye to the polypeptide was qualitatively confirmed by SDS-PAGE, and is shown in FIG. 5(A). Fluorescent dye-conjugated anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5 is UV light without gel staining on SDS-PAGE. Visualized by exposure. In Figure 5 (A) (b), the position of the dye-conjugated polypeptide under UV light was compared with the marker in the bright field, and the position was on a copper-stained SDS-PAGE gel before dye-conjugation. It coincided with Fig. 5(A)(a)). The dye conjugation to anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5 was confirmed by fluorescence spectra, a fluorescent dye- The conjugated fusion protein cage showed a fluorescence spectrum, whereas the fusion protein cage before conjugation showed no fluorescence signal (Fig. 5(B)). HUVECs were sprinkled on 45-well plates, attached to the surface and incubated overnight. HUVECs were incubated for 15, 30, and 60 minutes with 1 uM or 10 uM dye-conjugated polypeptide. Figure 5(C) shows a fluorescent image of a dye-conjugated polypeptide-treated HUVEC and a merged image of a bright field. The shape of HUVECs becomes rounder as the concentration and incubation time of the dye-conjugated polypeptide increases, and round cells show a fluorescent signal. Anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ The anti-Flt1 peptide of -HPC5 binds to VEGFR1 (Flt1) in the HUVEC membrane and , VEGF inhibits the binding of VEGFR1 to inhibit intracellular angiogenesis signals. One of the intracellular angiogenesis signals induced by VEGFR1 is the PI-3K (phosphatidylinositol 3-kinase) pathway, an actin-regulating protein for lamellipodia protrude and cell elongation. ) To regulate endothelial cell motility during cell migration. In the fluorescence image of HUVECs shown in FIG. 5(C), HUVECs treated with a high concentration of dye-conjugated polypeptide for a long time were anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34- mer-EBPP[A ₁ G ₄ I ₁ ] ₆ interacted more with anti-Flt1 of -HPC5, and HUVECs rounded up to show a fluorescent signal.

The application of the fusion polypeptide as a cell imaging probe has been studied through fluorescence HUVEC images. Another application of the fusion polypeptide is to synthesize gold nanoparticles (AuNPs) inside the cage structure and introduce them to Raman dyes for Raman sensing. The HPC of the fusion protein cage had an inorganic ion binding site containing gold ions. Anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5 is HPC, which has the most effective inhibition of angiogenesis and has the potential as a cell imaging probe. It was incubated with gold ions to coordinate The gold ions coordinated to the HPC were reduced to gold seeds by a reducing agent, and the gold seeds grew into gold nanoparticles by the addition of gold ions and a reducing agent. Figure 6(A) shows (a) before incubation with gold ions, (b) after addition of gold ions and first reduction, and (c) after second reduction, anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ Shows the size of -HPC5. UV-VIS absorbance at each step is shown in Fig. 6(B). Coordinated gold ions were reduced, seeded inside the HPC, and the seed grew until the empty pores were filled. The size of the fusion protein cage was constant during AuNP synthesis as shown in Fig. 6(A). The synthesis of AuNP was verified by the absorption spectrum, after the second reduction, only anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer-EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5 The absorbance was shown at 520 nm from AuNP (Fig. 6(B)). 6(C) shows a TEM image of AuNP in the anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5. The size of the AuNP was about 10 nm, consistent with the radius of the reported inner hole of the HPC. To evaluate the AuNP-anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5 complex as a Raman probe, Raman The dye MGITC (Malachite Green isothiocyanate) was introduced on the AuNP surface using the pH reactivity of HPC. HPC has reversible pH reactivity, so the structure collapses under acidic conditions and restores its original structure at natural pH. AuNP- anti-Flt1-HPC4- EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC of HPC5 complex adjusts the pH to introduce MGITC to the AuNP surface. It loosened as it decreased to 6, and the structure was restored upon adapting to pH 7.4. AuNP-anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer-EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5 complex incubated with 10 nM MGITC is shown in FIG. 6(D) It showed a meaningful Raman spectrum. The potential of anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer-EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5 as a cell imaging and Raman probe is based on the HUVEC imaging and Raman spectrum. Proved through.

Anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5 is a cage with a multivalent double angiogenesis inhibitory peptide. It was precisely controlled at the genetic level to expose anti-angiogenic peptides, anti-Flt1 peptide and PEDF 34-mer, without interfering with self-assembly into structures. Two types of anti-angiogenic peptides, anti-Flt1 peptide and PEDF 34-mer, had different mechanisms for angiogenesis inhibition, which were associated with intracellular signaling. Anti-Flt1-peptide inhibited intracellular signals for angiogenesis, and PEDF 34-mer triggered anti-angiogenic signals. These different mechanisms influenced the dose of the fusion protein cage in the in vitro tube formation investigation. In the investigation of in vitro tube formation of HUVECs, the fusion protein cage gradually decreased tube formation of HUVECs as the concentration of the polypeptide increased with the type of anti-angiogenic peptide. The fusion protein cage with anti-Flt1 peptide showed anti-angiogenic effects in the uM range, while the fusion protein cage with PEDF 34-mer inhibited the tube formation of HUVECs in the nM range. Anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer-EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5, a fusion protein cage containing two anti-angiogenic peptides It showed the greatest inhibitory effect in a wide concentration range. Fluorescent dye-conjugated anti-Flt1-HPC4-EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5 is the cell elongation irradiated by HUVEC imaging ( Cell extension) inhibition, showed the ability as a cell imaging probe. AuNP- anti-Flt1-HPC4- EBPP[A ₁ G ₄ I ₁ ] ₆ -PEDF 34-mer- EBPP[A ₁ G ₄ I ₁ ] ₆ -HPC5 is Raman spectra by introducing MGITC to the AuNP surface. Suggested. The fusion protein cage comprising two different anti-angiogenic peptides and HPCs according to the present invention is a therapeutic peptide for anti-angiogenesis, and has tremendous potential for tracking the course of anti-angiogenic related diseases.

Self-assembled protein nanostructures have been studied by fusion with functional peptides for use in theranostics and nanomedicines. In the present invention, a vascular endothelial growth factor receptor (VEGFR) targeting peptide, a functional 34-mer peptide of pigment epithelial-derived factor (PEDF) for inhibiting angiogenesis, After genetically engineering a fusion polypeptide consisting of an elastin-based polypeptide (EBP) having temperature reactivity and a helix-based protein cage (HPC), it was overexpressed in E. coli . , As part of a non-chromatographic method, it was purified by inverse transition cycling (ITC). The VEGFR targeting peptide and the anti-angiogenic PEDF 34-mer peptide were exposed to the self-assembled protein cage, and EBPs were introduced as non-chromatographic purification tags. The physicochemical properties and DySA (Dynamic self-assembly) of a fusion protein cage with a multivalent double angiogenesis inhibitory peptide were characterized. The fusion protein cage inhibited cell migration and tube formation of human umbilical vein endothelial cells (HUVECs) in the matrigel, which showed the potential as a nano-unit biopharmaceutical for the inhibition of angiogenesis. Since the fusion protein cage has an angiogenesis inhibitory effect, a fluorescent dye is chemically conjugated to the protein cage or metallic nanoparticles (MNPs), so that the fusion protein cage can be converted into fluorescent nanoprobes or inorganic- The organic hybrid surface-enhanced Raman scattering method was prepared with nanoprobes (inorganic-organic hybrid SERS nanoprobes). For example, gold, silver, copper, and iron nanoparticles can be chemically conjugated with a Raman dye to be used to label for teranostic and nanomedicine applications. The present invention is a fusion protein cage having a multivalent double angiogenesis inhibitory peptide, a therapeutic agent for uncontrolled retinal, corneal, and choroidal neovascular disease, tumor growth, cancer cell metastasis, diabetic retinopathy, and asthma, and at the same time for their growth It shows that it can be used in the field of teranostics and nanomedicine as bioimaging and biosensing for Korea.

<110> Industry-University Cooperation Foundation Hanyang University ERICA Campus <120> Anti-angiogenic fusion polypeptides, fusion protein cages with multivalent dual anti-angiogenic peptides, and their theranostics applications <130> DHP19-253P <150> KR 19/0045484 <151> 2019-04-18 <160> 22 <170> KoPatentIn 3.0 <210> 1 <211> 156 <212> PRT <213> Artificial Sequence <220> <223> helix-based protein cage <400> 1 Ser Ser Gln Ile Arg Gln Asn Tyr Ser Thr Asp Val Glu Ala Ala Val 1 5 10 15 Asn Ser Leu Val Asn Leu Tyr Leu Gln Ala Ser Tyr Thr Tyr Leu Ser 20 25 30 Leu Gly Phe Tyr Phe Asp Arg Asp Asp Val Ala Leu Glu Gly Val Ser 35 40 45 His Phe Phe Arg Glu Leu Ala Glu Glu Lys Arg Glu Gly Tyr Glu Arg 50 55 60 Leu Leu Lys Met Gln Asn Gln Arg Gly Gly Arg Ala Leu Phe Gln Asp 65 70 75 80 Ile Lys Lys Pro Ala Glu Asp Glu Trp Gly Lys Thr Pro Asp Ala Met 85 90 95 Lys Ala Ala Met Ala Leu Glu Lys Lys Leu Asn Gln Ala Leu Leu Asp 100 105 110 Leu His Ala Leu Gly Ser Ala Arg Thr Asp Pro His Leu Cys Asp Phe 115 120 125 Leu Glu Thr His Phe Leu Asp Glu Glu Val Lys Leu Ile Lys Lys Met 130 135 140 Gly Asp His Leu Thr Asn Leu His Arg Leu Gly Gly 145 150 155 <210> 2 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> helix-based protein cage <400> 2 Pro Glu Ala Gly Leu Gly Glu Tyr Leu Phe Glu Arg Leu Thr Leu Lys 1 5 10 15 His Asp <210> 3 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Anti-Flt1 peptide <400> 3 Gly Asn Gln Trp Phe Ile 1 5 <210> 4 <211> 34 <212> PRT <213> Artificial Sequence <220> <223> PEDF 34-mer <400> 4 Asp Pro Phe Phe Lys Val Pro Val Asn Lys Leu Ala Ala Ala Val Ser 1 5 10 15 Asn Phe Gly Tyr Asp Leu Tyr Arg Val Arg Ser Ser Thr Ser Pro Thr 20 25 30 Thr Asn <210> 5 <211> 30 <212> PRT <213> Artificial Sequence <220> <223> Elastin-based peptide <400> 5 Val Pro Gly Gly Gly Val Pro Gly Ala Gly Val Pro Gly Gly Gly Val 1 5 10 15 Pro Gly Gly Gly Val Pro Gly Ile Gly Val Pro Gly Gly Gly 20 25 30 <210> 6 <211> 30 <212> PRT <213> Artificial Sequence <220> <223> Elastin-based peptide <400> 6 Val Pro Ala Gly Gly Val Pro Ala Ala Gly Val Pro Ala Gly Gly Val 1 5 10 15 Pro Ala Gly Gly Val Pro Ala Ile Gly Val Pro Ala Gly Gly 20 25 30 <210> 7 <211> 30 <212> PRT <213> Artificial Sequence <220> <223> helix-based protein cage <400> 7 Val Pro Gly Gly Gly Val Pro Gly Lys Gly Val Pro Gly Gly Gly Val 1 5 10 15 Pro Gly Gly Gly Val Pro Gly Ile Gly Val Pro Gly Gly Gly 20 25 30 <210> 8 <211> 30 <212> PRT <213> Artificial Sequence <220> <223> Elastin-based peptide <400> 8 Val Pro Ala Gly Gly Val Pro Ala Lys Gly Val Pro Ala Gly Gly Val 1 5 10 15 Pro Ala Gly Gly Val Pro Ala Ile Gly Val Pro Ala Gly Gly 20 25 30 <210> 9 <211> 30 <212> PRT <213> Artificial Sequence <220> <223> Elastin-based peptide <400> 9 Val Pro Gly Gly Gly Val Pro Gly Asp Gly Val Pro Gly Gly Gly Val 1 5 10 15 Pro Gly Gly Gly Val Pro Gly Ile Gly Val Pro Gly Gly Gly 20 25 30 <210> 10 <211> 30 <212> PRT <213> Artificial Sequence <220> <223> Elastin-based peptide <400> 10 Val Pro Ala Gly Gly Val Pro Ala Asp Gly Val Pro Ala Gly Gly Val 1 5 10 15 Pro Ala Gly Gly Val Pro Ala Ile Gly Val Pro Ala Gly Gly 20 25 30 <210> 11 <211> 30 <212> PRT <213> Artificial Sequence <220> <223> Elastin-based peptide <400> 11 Val Pro Gly Gly Gly Val Pro Gly Glu Gly Val Pro Gly Gly Gly Val 1 5 10 15 Pro Gly Gly Gly Val Pro Gly Ile Gly Val Pro Gly Gly Gly 20 25 30 <210> 12 <211> 30 <212> PRT <213> Artificial Sequence <220> <223> Elastin-based peptide <400> 12 Val Pro Ala Gly Gly Val Pro Ala Glu Gly Val Pro Ala Gly Gly Val 1 5 10 15 Pro Ala Gly Gly Val Pro Ala Ile Gly Val Pro Ala Gly Gly 20 25 30 <210> 13 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Elastin-based peptide <400> 13 Gly Asn Gln Trp Phe Ile 1 5 <210> 14 <211> 360 <212> PRT <213> Artificial Sequence <220> <223> Elastin-based peptide <400> 14 Val Pro Ala Gly Gly Val Pro Ala Ala Gly Val Pro Ala Gly Gly Val 1 5 10 15 Pro Ala Gly Gly Val Pro Ala Ile Gly Val Pro Ala Gly Gly Val Pro 20 25 30 Ala Gly Gly Val Pro Ala Ala Gly Val Pro Ala Gly Gly Val Pro Ala 35 40 45 Gly Gly Val Pro Ala Ile Gly Val Pro Ala Gly Gly Val Pro Ala Gly 50 55 60 Gly Val Pro Ala Ala Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly 65 70 75 80 Val Pro Ala Ile Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val 85 90 95 Pro Ala Ala Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro 100 105 110 Ala Ile Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala 115 120 125 Ala Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ile 130 135 140 Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ala Gly 145 150 155 160 Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ile Gly Val 165 170 175 Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ala Gly Val Pro 180 185 190 Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ile Gly Val Pro Ala 195 200 205 Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ala Gly Val Pro Ala Gly 210 215 220 Gly Val Pro Ala Gly Gly Val Pro Ala Ile Gly Val Pro Ala Gly Gly 225 230 235 240 Val Pro Ala Gly Gly Val Pro Ala Ala Gly Val Pro Ala Gly Gly Val 245 250 255 Pro Ala Gly Gly Val Pro Ala Ile Gly Val Pro Ala Gly Gly Val Pro 260 265 270 Ala Gly Gly Val Pro Ala Ala Gly Val Pro Ala Gly Gly Val Pro Ala 275 280 285 Gly Gly Val Pro Ala Ile Gly Val Pro Ala Gly Gly Val Pro Ala Gly 290 295 300 Gly Val Pro Ala Ala Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly 305 310 315 320 Val Pro Ala Ile Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val 325 330 335 Pro Ala Ala Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro 340 345 350 Ala Ile Gly Val Pro Ala Gly Gly 355 360 <210> 15 <211> 534 <212> PRT <213> Artificial Sequence <220> <223> HPC4-EBPP[A1G4I1]12-HPC5 <400> 15 Ser Ser Gln Ile Arg Gln Asn Tyr Ser Thr Asp Val Glu Ala Ala Val 1 5 10 15 Asn Ser Leu Val Asn Leu Tyr Leu Gln Ala Ser Tyr Thr Tyr Leu Ser 20 25 30 Leu Gly Phe Tyr Phe Asp Arg Asp Asp Val Ala Leu Glu Gly Val Ser 35 40 45 His Phe Phe Arg Glu Leu Ala Glu Glu Lys Arg Glu Gly Tyr Glu Arg 50 55 60 Leu Leu Lys Met Gln Asn Gln Arg Gly Gly Arg Ala Leu Phe Gln Asp 65 70 75 80 Ile Lys Lys Pro Ala Glu Asp Glu Trp Gly Lys Thr Pro Asp Ala Met 85 90 95 Lys Ala Ala Met Ala Leu Glu Lys Lys Leu Asn Gln Ala Leu Leu Asp 100 105 110 Leu His Ala Leu Gly Ser Ala Arg Thr Asp Pro His Leu Cys Asp Phe 115 120 125 Leu Glu Thr His Phe Leu Asp Glu Glu Val Lys Leu Ile Lys Lys Met 130 135 140 Gly Asp His Leu Thr Asn Leu His Arg Leu Gly Gly Val Pro Ala Gly 145 150 155 160 Gly Val Pro Ala Ala Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly 165 170 175 Val Pro Ala Ile Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val 180 185 190 Pro Ala Ala Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro 195 200 205 Ala Ile Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala 210 215 220 Ala Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ile 225 230 235 240 Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ala Gly 245 250 255 Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ile Gly Val 260 265 270 Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ala Gly Val Pro 275 280 285 Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ile Gly Val Pro Ala 290 295 300 Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ala Gly Val Pro Ala Gly 305 310 315 320 Gly Val Pro Ala Gly Gly Val Pro Ala Ile Gly Val Pro Ala Gly Gly 325 330 335 Val Pro Ala Gly Gly Val Pro Ala Ala Gly Val Pro Ala Gly Gly Val 340 345 350 Pro Ala Gly Gly Val Pro Ala Ile Gly Val Pro Ala Gly Gly Val Pro 355 360 365 Ala Gly Gly Val Pro Ala Ala Gly Val Pro Ala Gly Gly Val Pro Ala 370 375 380 Gly Gly Val Pro Ala Ile Gly Val Pro Ala Gly Gly Val Pro Ala Gly 385 390 395 400 Gly Val Pro Ala Ala Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly 405 410 415 Val Pro Ala Ile Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val 420 425 430 Pro Ala Ala Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro 435 440 445 Ala Ile Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala 450 455 460 Ala Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ile 465 470 475 480 Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ala Gly 485 490 495 Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ile Gly Val 500 505 510 Pro Ala Gly Gly Pro Glu Ala Gly Leu Gly Glu Tyr Leu Phe Glu Arg 515 520 525 Leu Thr Leu Lys His Asp 530 <210> 16 <211> 540 <212> PRT <213> Artificial Sequence <220> <223> Anti-Flt1-HPC4-EBPP[A1G4I1]12-HPC5 <400> 16 Gly Asn Gln Trp Phe Ile Ser Ser Gln Ile Arg Gln Asn Tyr Ser Thr 1 5 10 15 Asp Val Glu Ala Ala Val Asn Ser Leu Val Asn Leu Tyr Leu Gln Ala 20 25 30 Ser Tyr Thr Tyr Leu Ser Leu Gly Phe Tyr Phe Asp Arg Asp Asp Val 35 40 45 Ala Leu Glu Gly Val Ser His Phe Phe Arg Glu Leu Ala Glu Glu Lys 50 55 60 Arg Glu Gly Tyr Glu Arg Leu Leu Lys Met Gln Asn Gln Arg Gly Gly 65 70 75 80 Arg Ala Leu Phe Gln Asp Ile Lys Lys Pro Ala Glu Asp Glu Trp Gly 85 90 95 Lys Thr Pro Asp Ala Met Lys Ala Ala Met Ala Leu Glu Lys Lys Leu 100 105 110 Asn Gln Ala Leu Leu Asp Leu His Ala Leu Gly Ser Ala Arg Thr Asp 115 120 125 Pro His Leu Cys Asp Phe Leu Glu Thr His Phe Leu Asp Glu Glu Val 130 135 140 Lys Leu Ile Lys Lys Met Gly Asp His Leu Thr Asn Leu His Arg Leu 145 150 155 160 Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ala Gly Val Pro Ala Gly 165 170 175 Gly Val Pro Ala Gly Gly Val Pro Ala Ile Gly Val Pro Ala Gly Gly 180 185 190 Val Pro Ala Gly Gly Val Pro Ala Ala Gly Val Pro Ala Gly Gly Val 195 200 205 Pro Ala Gly Gly Val Pro Ala Ile Gly Val Pro Ala Gly Gly Val Pro 210 215 220 Ala Gly Gly Val Pro Ala Ala Gly Val Pro Ala Gly Gly Val Pro Ala 225 230 235 240 Gly Gly Val Pro Ala Ile Gly Val Pro Ala Gly Gly Val Pro Ala Gly 245 250 255 Gly Val Pro Ala Ala Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly 260 265 270 Val Pro Ala Ile Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val 275 280 285 Pro Ala Ala Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro 290 295 300 Ala Ile Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala 305 310 315 320 Ala Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ile 325 330 335 Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ala Gly 340 345 350 Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ile Gly Val 355 360 365 Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ala Gly Val Pro 370 375 380 Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ile Gly Val Pro Ala 385 390 395 400 Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ala Gly Val Pro Ala Gly 405 410 415 Gly Val Pro Ala Gly Gly Val Pro Ala Ile Gly Val Pro Ala Gly Gly 420 425 430 Val Pro Ala Gly Gly Val Pro Ala Ala Gly Val Pro Ala Gly Gly Val 435 440 445 Pro Ala Gly Gly Val Pro Ala Ile Gly Val Pro Ala Gly Gly Val Pro 450 455 460 Ala Gly Gly Val Pro Ala Ala Gly Val Pro Ala Gly Gly Val Pro Ala 465 470 475 480 Gly Gly Val Pro Ala Ile Gly Val Pro Ala Gly Gly Val Pro Ala Gly 485 490 495 Gly Val Pro Ala Ala Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly 500 505 510 Val Pro Ala Ile Gly Val Pro Ala Gly Gly Pro Glu Ala Gly Leu Gly 515 520 525 Glu Tyr Leu Phe Glu Arg Leu Thr Leu Lys His Asp 530 535 540 <210> 17 <211> 568 <212> PRT <213> Artificial Sequence <220> <223> HPC4- EBPP[A1G4I1]6-PEDF 34-mer- EBPP[A1G4I1]6-HPC5 <400> 17 Ser Ser Gln Ile Arg Gln Asn Tyr Ser Thr Asp Val Glu Ala Ala Val 1 5 10 15 Asn Ser Leu Val Asn Leu Tyr Leu Gln Ala Ser Tyr Thr Tyr Leu Ser 20 25 30 Leu Gly Phe Tyr Phe Asp Arg Asp Asp Val Ala Leu Glu Gly Val Ser 35 40 45 His Phe Phe Arg Glu Leu Ala Glu Glu Lys Arg Glu Gly Tyr Glu Arg 50 55 60 Leu Leu Lys Met Gln Asn Gln Arg Gly Gly Arg Ala Leu Phe Gln Asp 65 70 75 80 Ile Lys Lys Pro Ala Glu Asp Glu Trp Gly Lys Thr Pro Asp Ala Met 85 90 95 Lys Ala Ala Met Ala Leu Glu Lys Lys Leu Asn Gln Ala Leu Leu Asp 100 105 110 Leu His Ala Leu Gly Ser Ala Arg Thr Asp Pro His Leu Cys Asp Phe 115 120 125 Leu Glu Thr His Phe Leu Asp Glu Glu Val Lys Leu Ile Lys Lys Met 130 135 140 Gly Asp His Leu Thr Asn Leu His Arg Leu Gly Gly Val Pro Ala Gly 145 150 155 160 Gly Val Pro Ala Ala Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly 165 170 175 Val Pro Ala Ile Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val 180 185 190 Pro Ala Ala Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro 195 200 205 Ala Ile Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala 210 215 220 Ala Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ile 225 230 235 240 Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ala Gly 245 250 255 Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ile Gly Val 260 265 270 Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ala Gly Val Pro 275 280 285 Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ile Gly Val Pro Ala 290 295 300 Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ala Gly Val Pro Ala Gly 305 310 315 320 Gly Val Pro Ala Gly Gly Val Pro Ala Ile Gly Val Pro Ala Gly Gly 325 330 335 Asp Pro Phe Phe Lys Val Pro Val Asn Lys Leu Ala Ala Ala Val Ser 340 345 350 Asn Phe Gly Tyr Asp Leu Tyr Arg Val Arg Ser Ser Thr Ser Pro Thr 355 360 365 Thr Asn Val Pro Ala Gly Gly Val Pro Ala Ala Gly Val Pro Ala Gly 370 375 380 Gly Val Pro Ala Gly Gly Val Pro Ala Ile Gly Val Pro Ala Gly Gly 385 390 395 400 Val Pro Ala Gly Gly Val Pro Ala Ala Gly Val Pro Ala Gly Gly Val 405 410 415 Pro Ala Gly Gly Val Pro Ala Ile Gly Val Pro Ala Gly Gly Val Pro 420 425 430 Ala Gly Gly Val Pro Ala Ala Gly Val Pro Ala Gly Gly Val Pro Ala 435 440 445 Gly Gly Val Pro Ala Ile Gly Val Pro Ala Gly Gly Val Pro Ala Gly 450 455 460 Gly Val Pro Ala Ala Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly 465 470 475 480 Val Pro Ala Ile Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val 485 490 495 Pro Ala Ala Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro 500 505 510 Ala Ile Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala 515 520 525 Ala Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ile 530 535 540 Gly Val Pro Ala Gly Gly Pro Glu Ala Gly Leu Gly Glu Tyr Leu Phe 545 550 555 560 Glu Arg Leu Thr Leu Lys His Asp 565 <210> 18 <211> 574 <212> PRT <213> Artificial Sequence <220> <223> Anti-Flt1-HPC4- EBPP[A1G4I1]6-PEDF 34-mer- EBPP[A1G4I1]6-HPC5 <400> 18 Gly Asn Gln Trp Phe Ile Ser Ser Gln Ile Arg Gln Asn Tyr Ser Thr 1 5 10 15 Asp Val Glu Ala Ala Val Asn Ser Leu Val Asn Leu Tyr Leu Gln Ala 20 25 30 Ser Tyr Thr Tyr Leu Ser Leu Gly Phe Tyr Phe Asp Arg Asp Asp Val 35 40 45 Ala Leu Glu Gly Val Ser His Phe Phe Arg Glu Leu Ala Glu Glu Lys 50 55 60 Arg Glu Gly Tyr Glu Arg Leu Leu Lys Met Gln Asn Gln Arg Gly Gly 65 70 75 80 Arg Ala Leu Phe Gln Asp Ile Lys Lys Pro Ala Glu Asp Glu Trp Gly 85 90 95 Lys Thr Pro Asp Ala Met Lys Ala Ala Met Ala Leu Glu Lys Lys Leu 100 105 110 Asn Gln Ala Leu Leu Asp Leu His Ala Leu Gly Ser Ala Arg Thr Asp 115 120 125 Pro His Leu Cys Asp Phe Leu Glu Thr His Phe Leu Asp Glu Glu Val 130 135 140 Lys Leu Ile Lys Lys Met Gly Asp His Leu Thr Asn Leu His Arg Leu 145 150 155 160 Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ala Gly Val Pro Ala Gly 165 170 175 Gly Val Pro Ala Gly Gly Val Pro Ala Ile Gly Val Pro Ala Gly Gly 180 185 190 Val Pro Ala Gly Gly Val Pro Ala Ala Gly Val Pro Ala Gly Gly Val 195 200 205 Pro Ala Gly Gly Val Pro Ala Ile Gly Val Pro Ala Gly Gly Val Pro 210 215 220 Ala Gly Gly Val Pro Ala Ala Gly Val Pro Ala Gly Gly Val Pro Ala 225 230 235 240 Gly Gly Val Pro Ala Ile Gly Val Pro Ala Gly Gly Val Pro Ala Gly 245 250 255 Gly Val Pro Ala Ala Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly 260 265 270 Val Pro Ala Ile Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val 275 280 285 Pro Ala Ala Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro 290 295 300 Ala Ile Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala 305 310 315 320 Ala Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ile 325 330 335 Gly Val Pro Ala Gly Gly Asp Pro Phe Phe Lys Val Pro Val Asn Lys 340 345 350 Leu Ala Ala Ala Val Ser Asn Phe Gly Tyr Asp Leu Tyr Arg Val Arg 355 360 365 Ser Ser Thr Ser Pro Thr Thr Asn Val Pro Ala Gly Gly Val Pro Ala 370 375 380 Ala Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ile 385 390 395 400 Gly Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ala Gly 405 410 415 Val Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ile Gly Val 420 425 430 Pro Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ala Gly Val Pro 435 440 445 Ala Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ile Gly Val Pro Ala 450 455 460 Gly Gly Val Pro Ala Gly Gly Val Pro Ala Ala Gly Val Pro Ala Gly 465 470 475 480 Gly Val Pro Ala Gly Gly Val Pro Ala Ile Gly Val Pro Ala Gly Gly 485 490 495 Val Pro Ala Gly Gly Val Pro Ala Ala Gly Val Pro Ala Gly Gly Val 500 505 510 Pro Ala Gly Gly Val Pro Ala Ile Gly Val Pro Ala Gly Gly Val Pro 515 520 525 Ala Gly Gly Val Pro Ala Ala Gly Val Pro Ala Gly Gly Val Pro Ala 530 535 540 Gly Gly Val Pro Ala Ile Gly Val Pro Ala Gly Gly Pro Glu Ala Gly 545 550 555 560 Leu Gly Glu Tyr Leu Phe Glu Arg Leu Thr Leu Lys His Asp 565 570 <210> 19 <211> 66 <212> DNA <213> Artificial Sequence <220> <223> oligonucleotide <400> 19 ctagaaataa ttttgtttaa ctttaagaag gaggagtaca tatgggctac tgataatgat 60 cttcag 66 <210> 20 <211> 66 <212> DNA <213> Artificial Sequence <220> <223> oligonucleotide <400> 20 gatcctgaag atcattatca gtagcccata tgtactcctc cttcttaaag ttaaacaaaa 60 ttattt 66 <210> 21 <211> 40 <212> DNA <213> Artificial Sequence <220> <223> forward primer <400> 21 aaaggatccc cctactggta atgctcttca gtctagagat 40 <210> 22 <211> 40 <212> DNA <213> Artificial Sequence <220> <223> reverse primer <400> 22 cacgaccaac ggctactgat agtgatcttc agctagcgat 40

Claims (14)

i) anti-angiogenic peptides; A helix-based polypeptide represented by SEQ ID NO: 1 linked to the peptide; A hydrophilic elastin-based polypeptide (hydrophilic EBP) linked to the helix-based peptide; Consisting of a helix-based polypeptide represented by SEQ ID NO: 2 linked to the hydrophilic EBP, or
ii) a helix-based polypeptide represented by SEQ ID NO: 1; Hydrophilic EBP linked to the peptide; An anti-angiogenic peptide linked to the first hydrophilic EBP; A second hydrophilic EBP linked to the anti-angiogenic peptide; And a helix-based polypeptide represented by SEQ ID NO: 2 linked to the hydrophilic EBP, or
iii) anti-angiogenic peptides; A helix-based polypeptide represented by SEQ ID NO: 1 linked to the peptide; Hydrophilic EBP linked to the helix-based polypeptide; Anti-angiogenic peptide linked to the hydrophilic EBP; Hydrophilic EBP linked to the anti-angiogenic peptide; And that consisting of a helix-based polypeptide represented by SEQ ID NO: 2 linked to the hydrophilic EBP, a fusion polypeptide for inhibiting new angiogenesis.
The method of claim 1,
The anti-angiogenic peptide is an anti-Flt1 peptide [SEQ ID NO: 3] or PEDF (pigment epithelial-derived factor) 34-mer [SEQ ID NO: 4], a fusion polypeptide for inhibiting new angiogenesis.
The method of claim 1,
The hydrophilic EBP,
Which is represented by one of SEQ ID NOs: 5 to 14, the fusion polypeptide for inhibiting the generation of new blood vessels.
The method of claim 1,
The i) is composed of [anti-Flt1 peptide of SEQ ID NO: 3]-[helix-based polypeptide represented by SEQ ID NO: 1]-[hydrophilic EBP]-[helix-based polypeptide represented by SEQ ID NO:2] , Fusion polypeptide for inhibiting the generation of new blood vessels.
The method of claim 1,
The ii) is [Helix-based polypeptide represented by SEQ ID NO: 1]-[Hydrophilic EBP]-[PEDF 34-mer of SEQ ID NO:4]-[Hydrophilic EBP]-[Helix-based polypeptide represented by SEQ ID NO:2] Consisting of, a fusion polypeptide for inhibiting new angiogenesis.
The method of claim 1,
Iii) above
[Anti-Flt1 peptide of SEQ ID NO: 3]-[Helix-based polypeptide represented by SEQ ID NO: 1]-[Hydrophilic EBP]-[PEDF 34-mer of SEQ ID NO:4]-[Hydrophilic EBP]-[SEQ ID NO:2] Helix-based polypeptide shown] that is composed of, a fusion polypeptide for inhibiting the generation of new blood vessels.
The method of claim 1,
The i) is SEQ ID NO: 16, ii) is SEQ ID NO: 17, and iii) is represented by SEQ ID NO: 18, the fusion polypeptide for inhibiting neovascularization.
A composition for the treatment of diseases caused by neovascularization, comprising the fusion polypeptide for inhibiting neovascularization according to any one of claims 1 to 7.
The method of claim 8,
Diseases caused by neovascularization include diabetic retinopathy, retinopathy of premature infants, macular degeneration, choroidal neovascularization, neovascular glaucoma, ocular disease due to corneal angiogenesis, rejection during corneal transplantation, Corneal edema, corneal opacity, cancer (cancer), hemangioma, hemangiofibroma, rheumatoid arthritis (rheumatoid arthritis), and any one or more selected from psoriasis, a composition for the treatment of diseases caused by neovascularization.
In the fusion polypeptide for inhibiting neovascularization according to any one of claims 1 to 7, a helix-based polypeptide represented by SEQ ID NO: 1 and a helix-based polypeptide represented by SEQ ID NO: 2 are prepared by self-assembly. That is, a fusion protein nanocage having a peptide for inhibiting neovascularization.
The method of claim 10,
The nanocage is a fusion protein nanocage having a peptide for inhibiting new angiogenesis, characterized in that it has a multivalent fusion polypeptide for inhibiting new angiogenesis.
Fluorescent dyes; And
A fusion protein nanocage having a peptide for inhibiting new angiogenesis according to claim 10;
Including,
The fluorescent dye is contained in the nano-cage, a teranostic nanoprobe for diseases caused by neovascularization.
Metal nanoparticles bound with Raman dye; And
A fusion protein nanocage having a peptide for inhibiting new angiogenesis according to claim 10;
Including,
The Raman dye-coupled metal nanoparticles are contained in the nanocage, and theranostic nanoprobe for diseases caused by neovascularization.
The method of claim 12 or 13,
Diseases caused by neovascularization include diabetic retinopathy, retinopathy of premature infants, macular degeneration, choroidal neovascularization, neovascular glaucoma, ocular disease due to corneal angiogenesis, rejection during corneal transplantation, Corneal edema, corneal opacity, cancer (cancer), hemangioma, hemangiofibroma, rheumatoid arthritis (rheumatoid arthritis), and any one or more selected from psoriasis theranostic nanoprobe.

Images